Spenser Lin No Comments

Healthcare News, Deals, and Investments Update November 16th, 2026

  1. Apple launches a research study with OpenEvidence to explore how people use conversational AI for health. The Apple Health AI Usage Study is a virtual research study and app open to up to 200,000 eligible U.S. participants aged 21 and older. Participants can ask everyday health questions, explore medical information with linked peer-reviewed citations, and optionally share HealthKit data such as resting heart rate, activity, sleep and lab results. The study is conducted with OpenEvidence, a clinical AI platform that draws on sources including The New England Journal of Medicine and JAMA. Data will not be used to train AI models, and participants control what they share. The study is intended to inform the responsible design of health AI experiences. (Link)
  2. Surgery Partners (NASD: SGRY) and HealthSpan Partners raise the take-private price to $25.00 per share, up to about $6.0 billion, with Bain Capital rolling its 39% stake. Surgery Partners and HealthSpan Partners, an affiliate of Bon Secours Mercy Health, amended their merger agreement and raised the cash price from $23.50 to $25.00 per share. Holders other than Bain receive a ticking fee of 10% a year, capped at $1.61 per share, if stockholders approve before March 1, 2027 and the deal has not closed. The special committee determined a nonbinding $28-per-share proposal, reported by Bloomberg to be from UnitedHealth Group, was not superior, citing a longer timeline and regulatory risk. Bain affiliates own about 39% and will roll their shares into the acquiring entity rather than cash out. (Link)
  3. Johnson & Johnson (NYSE: JNJ) agrees to acquire Ollin Biosciences for $2.2 billion upfront, plus up to $1.13 billion in milestones, adding a late-stage bispecific antibody for diabetic macular edema and wet AMD. Ollin’s lead asset, OLN324, is a bispecific antibody designed for diabetic macular edema and wet age-related macular degeneration, two conditions that affect more than 40 million people worldwide. Early head-to-head data suggested faster improvement in eye structure and vision than Roche’s Vabysmo. J&J also struck a separate $750 million multi-year development-funding agreement with Blackstone Life Sciences to help cover late-stage trials. The purchase expands J&J’s presence in ophthalmology beyond its existing contact-lens and surgical devices business. (Link)
  4. Eli Lilly (NYSE: LLY) agrees to acquire Calytrix Bio for up to $1.5 billion, adding a biparatopic antibody for mutant-CALR-driven essential thrombocythemia and myelofibrosis. Calytrix, founded in 2025 by J.P. Morgan Life Sciences Private Capital and based in Wellesley Hills, Massachusetts, is developing a novel biparatopic antibody designed for pan-mutant activity against Type 1 and Type 2 mCALR. The deal includes an upfront payment and subsequent clinical and regulatory milestones. Centerview Partners advised Calytrix. Mutant CALR is a tumor-specific cell-surface target that could allow selective depletion of the disease-driving clone while sparing normal tissues. (Link)
  5. Oura, a health intelligence platform and maker of the Oura Ring, agrees to acquire Counsel Health, an AI-native primary care company, for $625 million in cash. Counsel Health combines medical AI with in-house board-certified physicians to deliver on-demand clinical guidance and care. The acquisition embeds Counsel’s AI and physician network directly into the Oura app so members can escalate from biometric insights to licensed care. Counsel will continue serving health plans and employers, and it plans to offer hypertension and prediabetes care to eligible Medicare beneficiaries through CMS’s ACCESS Model in early 2027. Oura delayed its IPO in September; it reported 153% year-over-year revenue growth in its most recent quarter, to $533 million, and has more than 6 million members. (Link)
  6. Medtronic (NYSE: MDT) agrees to acquire Contego Medical, a private medical device company focused on carotid artery disease and peripheral thrombectomy, for $380 million, plus potential post-acquisition payments. The deal adds Contego’s Neuroguard IEP Direct System for transcarotid artery revascularization and its Excipio thrombectomy devices to Medtronic’s vascular portfolio. It builds on an existing exclusive U.S. distribution agreement. Neuroguard IEP is designed for carotid artery disease, while Excipio addresses peripheral thrombectomy. The transaction is expected to be minimally dilutive in the near term and neutral to accretive thereafter. (Link)
  7. MaxCyte (NASD: MXCT), a cell-engineering company, agrees to acquire Akron Bio, backed by Arcline Investment Management, for $151.8 million in cash, stock and deferred payments. Akron Bio supplies GMP-grade reagents and ancillary materials used throughout the cell therapy manufacturing workflow. The combination is expected to nearly double MaxCyte’s revenue base; Akron is projected to generate approximately $28 million in 2026 revenue and $7–8 million in EBITDA. MaxCyte also secured a credit facility of up to $75 million from MidCap Financial in connection with the deal. (Link)
  8. Wolters Kluwer Health agrees to acquire AgileMD, a clinical decision support company, for up to $100 million, including $40 million upfront and up to $60 million in performance-based deferred consideration. AgileMD provides AI-powered clinical pathways and eCART, an FDA-cleared real-time surveillance engine that predicts inpatient deterioration. The acquisition accelerates integration of UpToDate Expert AI inside EHR workflows so clinicians can act on evidence-based guidance without leaving the chart. AgileMD is projected to generate about $7 million in 2026 annual recurring revenue. The deferred consideration is tied to performance milestones over a multi-year period. (Link)
  9. Arcturus Therapeutics (NASD: ARCT) announces a $50 million equity investment by Meiji Seika Pharma at an 80% premium, as part of an expanded collaboration. Meiji will purchase unregistered shares at $20.27 each, representing 7.9% of Arcturus after the transaction. Proceeds will accelerate ARCT-2601 for ornithine transcarbamylase deficiency and clinically validate the LUNAR 2.0 mRNA platform. The companies also signed an exclusive license for ARCT-154 technology in an undisclosed area and a memorandum of understanding on pandemic preparedness in Japan. Meiji already distributes KOSTAIVE, Arcturus’ self-amplifying mRNA COVID-19 vaccine, in Japan. (Link)
  10. Ardent Health agrees to acquire Boone Health, a Missouri nonprofit health system, for $47 million in cash plus a $200 million capital commitment over 10 years. The transaction includes Boone Hospital Center, a 392-bed facility, Boone Health Medical Group, 19 care sites and related real estate. Ardent operates 30 acute-care hospitals and more than 200 sites of care across six states. The $200 million capital commitment runs over 10 years and is intended to support technology, facilities and physician recruitment. Nonprofit hospital acquisitions by for-profit operators remain active in secondary markets. (Link)
  11. Davion Healthcare (NASD: DAVI) agrees to terms to acquire the Independence Care homecare network for up to $10 million. Independence Care is a family-operated U.S. homecare provider with more than 15 years of experience. The agreement covers 14 businesses across ten states that generated about $17 million in 2025 revenue. Consideration includes $4.5 million in cash at signing, $3.5 million at milestones, $1 million in Davion shares, and up to $1 million in earnouts. Homecare remains an active consolidation segment for smaller public platforms. (Link)
  12. Lineage Cell Therapeutics (NYSE: LCTX) acquires NeuroAirmid Therapeutics and its clinical-stage HUNT1 cell therapy for Huntington’s disease for about $4.7 million upfront, plus up to $53 million in milestones. HUNT1 is a pluripotent stem cell-derived neural cell therapy in the Phase 1b/2a REGEN4HD study at UC Irvine, where six patients have been dosed. At closing Lineage paid $2.4 million in cash, issued 2.2 million shares, funded a $0.2 million expense fund and paid $1.7 million toward NeuroAirmid’s obligations. Additional payments of up to $5.4 million are due on the first anniversary and up to $48 million are tied to clinical and regulatory milestones. The therapy was built on the same cell line Lineage already uses for its AlloSCOPE platform. (Link)
  13. Inovalon, a healthcare cloud data and analytics company backed by Nordic Capital, agrees to acquire DrFirst, a clinical workflow and electronic prescribing technology provider. DrFirst embeds real-time formulary alternatives, therapeutic warnings, out-of-pocket pricing, automated prior authorizations and adherence tools into the electronic prescribing interface. The combination pairs Inovalon’s longitudinal data across hundreds of millions of patient lives with point-of-care medication management. The combined network reaches about 71,000 pharmacies and 670,000 providers. Inovalon plans to feed its claims and lab history into DrFirst’s prescribing workflow so clinicians see formulary alternatives and prior-authorization requirements during the visit. (Link)
  14. PAI Pharma, backed by Olympus Partners, acquires Nexus Pharmaceuticals, expanding its sterile injectable portfolio. Nexus brings more than 20 commercial hospital injectable products used in critical care, oncology and other settings, along with established customer relationships. The combination strengthens PAI’s presence in Ready-to-Use sterile injectables and hospital pharmaceuticals. Olympus Partners is the sponsor behind PAI. Sterile injectables continue to attract platform consolidators given hospital demand and limited domestic capacity. (Link)
  15. PromptCare Infusion, backed by Waud Capital, is sold to AOM Infusion, backed by Revelstoke Capital Partners, creating a national home and alternate-site infusion platform. PromptCare is a home and alternate-site infusion provider. Waud Capital reported a fivefold revenue increase during its hold, expanding the business from 19 states to all 50 and doubling its pharmacy network. AOM Infusion is backed by Revelstoke Capital Partners. The combination creates one of the larger independent home and alternate-site infusion platforms in the country. Waud will retain PromptCare’s complex respiratory and enteral nutrition business, making this a partial exit. (Link)
  16. Beni Solutions, a provider of ACA-compliant health plans for small and midsized employers, receives an investment from Aquiline Capital Partners. Beni Solutions provides ACA-compliant group health plans designed for small and midsized employers. Founded in 2022 and headquartered in Wayne, New Jersey, the platform serves more than 1,500 employers and more than 30,000 covered lives. The investment supports continued growth through sales, marketing and broker relationships. Alternative health plans continue to draw capital as small-employer premiums rise. (Link)
  17. Petauri, backed by Oak Hill Capital, acquires Emotive, a medical communications agency focused on neuroscience and immunology. Emotive adds depth in neuroscience and immunology medical communications to Petauri’s platform. Founded in 2013 and based in London with a Boston office, Emotive joins Petauri Advance alongside existing agencies DRIVE, PROPEL and MOMENTUM. Oak Hill Capital is the sponsor behind Petauri and has committed more than $250 million of equity capital to the platform. The acquisition expands Petauri’s medical-communications capabilities in specialty therapeutic areas. (Link)
  18. Healthcare Control Systems, maker of the ORControl operating-room coordination platform, receives a strategic investment from Ironleaf Capital. Healthcare Control Systems provides the ORControl platform used by HCA, Ascension, CommonSpirit and the Veterans Health Administration for operating-room coordination. This is the first investment for newly formed Ironleaf Capital, founded by former Veritas Capital partner T.J. Rose. The platform helps hospitals coordinate surgical schedules and resource allocation in real time. Operating-room workflow software is attracting lower-midmarket capital as hospitals look for capacity gains. (Link)
  19. Elligint Health acquires Laguna Health, embedding conversational AI care management across more than 13 million managed lives. Laguna Health will operate as a wholly owned subsidiary. Its tools include an AI co-pilot for pre-call preparation and post-call documentation, a quality-assurance engine that audits member calls, and an agentic assistant for autonomous outreach. Health plans can adopt the modules standalone or inside Elligint’s Helios platform. The combination embeds conversational AI care management across more than 13 million managed lives. (Link)
  20. XRHealth acquires PursueCare, expanding its virtual reality therapy platform into addiction care and FDA-authorized digital therapeutics. PursueCare provides virtual outpatient addiction treatment for alcohol, opioids, cannabis and co-occurring mental health conditions, plus the FDA-authorized RESET and RESET-O prescription digital therapeutics. XRHealth issued approximately $16.25 million in common stock to the sellers. The combination adds clinical teams, payer relationships and digital therapeutics to XRHealth’s spatial-computing care model. Virtual addiction treatment is consolidating as payers expand coverage for remote behavioral care. (Link)
  21. Parkview Health completes its acquisition of Ovation Healthcare, a shared-services company serving health systems and critical-access hospitals. Ovation provides leadership advisory, spend management, revenue cycle management and technology services to health systems and critical-access hospitals. The acquisition aims to deploy shared infrastructure that helps community and rural providers reduce administrative overhead. Ovation partners with more than 500 healthcare organizations across 48 states. Shared-services models remain a practical answer for smaller hospitals facing rising operating costs. (Link)
  22. BJC Health signs a letter of intent for St. Luke’s Hospital to join its system. St. Luke’s is based in Chesterfield, Missouri and operates a 493-bed hospital along with more than 60 specialties and 30 outpatient locations. BJC plans to invest in technology, facilities and physician recruitment as part of the combination. The letter of intent is non-binding, and the parties will work toward a definitive agreement and required regulatory reviews. The combination would expand BJC’s presence in the St. Louis market and give St. Luke’s access to WashU Medicine resources. (Link)
  23. Valo Health, backed by Flagship Pioneering, and Montai Therapeutics merge under the Valo name. The combined company will pair the two AI platforms behind an immunology pipeline led by Montai’s Phase 1 candidate MTAI-1025, an oral NRF2 agonist for ulcerative colitis. The merger combines Valo’s AI drug-discovery capabilities with Montai’s immunology assets. Flagship Pioneering is the sponsor behind Valo, and Brian Alexander will continue as CEO. Platform combinations among AI drug-discovery companies have become more common as sponsors look for clinical-stage assets. (Link)
  24. Northpoint Recovery acquires Brick House Recovery, adding three adult outpatient facilities and a statewide virtual program in Idaho. Brick House, founded in 2014, provides partial hospitalization, intensive outpatient and outpatient substance-use treatment in Boise, Idaho Falls and Coeur d’Alene, plus a statewide virtual program. Northpoint’s network grows from 20 to 23 facilities, including 12 adult outpatient sites. The two organizations have referred patients to each other for ten years. Outpatient behavioral platforms continue to consolidate as payers expand coverage for lower-intensity care. (Link)
  25. Beacon Behavioral Partners expands its Houston presence through a partnership with One Behavioral, adding six locations. One Behavioral specializes in remote and in-person outpatient medication management, Spravato treatment, transcranial magnetic stimulation, psychotherapy and psychological testing. It joins Beacon’s existing Houston partners Memorial Park Psychiatry and Hauser Clinic. Beacon is a Dallas-Fort Worth-based network of independent psychiatric practices. Agenda Health advised Beacon. Independent psychiatric practices continue to partner with management platforms to access shared infrastructure. (Link)
  26. Well Labs+ acquires Adoro Medical Spa, a Severna Park, Maryland medical spa led by board-certified oculoplastic surgeon Dr. Elba Pacheco. Adoro specializes in facial and skin rejuvenation. Well Labs+ is a 47-location medspa platform that acquires and partners with medspa owners while preserving the local brand. Dresner Partners advised Adoro. Medical-spa consolidation continues as multi-site platforms look for density in secondary markets. (Link)
  27. PharmaLogic acquires Lantheus’ radiopharmaceutical CDMO business and Springfield, N.J. plant. The acquisition adds Lantheus’ contract development and manufacturing capabilities and the Springfield, New Jersey facility to PharmaLogic’s radiopharmaceutical platform. The Springfield site has a track record in theranostic manufacturing and will join Agilera, PharmaLogic’s therapeutic CDMO franchise. The deal includes a long-term supply agreement under which Agilera will manufacture lutetium Lu 177 dotatate for Lantheus. The combination creates a transatlantic radioligand therapy manufacturing capability. (Link)

Venture Deals and Other

  1. Delix Therapeutics closes a $100 million Series C led by Johnson & Johnson Innovation – JJDC and SV Health Investors’ Dementia Discovery Fund. The financing will advance zalsupindole, Delix’s non-hallucinogenic neuroplastogen, into Phase 2. Johnson & Johnson Innovation – JJDC and SV Health Investors’ Dementia Discovery Fund co-led the round, with participation from RA Capital, UC Investments and others. Zalsupindole is designed to promote neuroplasticity without hallucinogenic effects, and Delix expects to start a Phase 2b study in major depressive disorder in the first half of 2027. The company has raised more than $200 million to date. (Link)
  2. Charta Health raises $55 million in Series B financing led by Insight Partners to expand its AI medical chart review platform for providers and payers. Existing investors Madrona, Bain Capital Ventures and South Park Commons participated, alongside QuantumLight. The round brings total funding to $85 million and supports the launch of dedicated offerings for both sides of the claim. Charta reviews charts against coding guidelines and payer rules before submission. The company has seen rapid revenue growth, reportedly 10x over the past 12 months, serving outpatient organizations across multiple specialties. (Link)
  3. Zus Health raises $33 million in Series B financing led by Drive Capital to scale its AI-native connected patient data platform. Sanofi Ventures, HealthX Ventures, Alumni Ventures, Andreessen Horowitz, F-Prime, Maverick Ventures and JAZZ Venture Partners also participated. The round brings total capital raised to more than $100 million. Founded by Jonathan Bush, co-founder of athenahealth, Zus unifies fragmented patient records into a networked medical record that supports AI-powered clinical workflows. The company processed more than 110 million networked transactions in a recent month. (Link)
  4. Nanopath raises a $25 million Series B co-led by Norwest and SV Health Investors’ MedTech Convergence Fund. The Labcorp Venture Fund also participated, alongside Elderberry Ventures, GingerBread Capital and Alumni Ventures. Nanopath develops rapid point-of-care molecular tests for women’s health, including a 15-minute vaginitis assay. The financing supports manufacturing scale-up and an FDA 510(k) clinical study, as well as potential expansion into UTIs and STIs. Norwest and SV Health Investors’ MedTech Convergence Fund co-led the round. (Link)
  5. Duet raises $15 million in Series A financing to scale its nurse-practitioner-owned clinic network and launch an NP-led Medicare Accountable Care Organization. The funding supports expansion of Duet’s model, which pairs nurse practitioners with operational and technology support so NPs can own and operate clinics. The company plans to launch the first NP-led Medicare ACO in 2027. Nurse-practitioner-owned primary care models are drawing early-stage capital as value-based care expands. (Link)
Spenser Lin No Comments

Lawrence, Evans & Co., LLC at HLTH USA 2026 Las Vegas | November 15–18, 2026

Managing Partner Neil Johnson will be at HLTH USA as Co-Founder of Healthcare Development & Innovation Group (HDIG), which is sponsoring the event. He remains available throughout the conference to discuss Lawrence, Evans & Co., LLC matters, including lower middle-market healthcare M&A, capital raising, and special situations.

Lawrence, Evans & Co., LLC advises lower middle-market healthcare companies (typically up to $250M in revenue and/or $15M in EBITDA) across providers, business services, and software. Core sectors include Behavioral Health & Mental Health, HCIT & Digital Health, Longevity, RCM, Physician Groups, Home Health, Hospice & Senior Housing, Pharma Services, Cyber & Managed IT, Supply Chain, Space Health & Life Science, and Innovation.

If you’re attending HLTH and would like to connect with Neil in person, please reach out in advance or stop by HDIG’s booth.

Schedule a meeting or meet us in person at Booth 127-84

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update November 9th, 2026

Election Results: Blue Wave?

  • Democrats flip control of the House and Senate, putting healthcare affordability, expired ACA subsidies and 2027 Medicaid work requirements at the top of the legislative agenda. Democrats won control of both chambers in the midterm elections, driven in part by voter concern over rising health insurance costs. Enhanced ACA premium subsidies expired at the end of 2025, producing sharp premium increases for millions. Medicaid work requirements enacted under the 2025 OBBBA are scheduled to begin in 2027. Democrats are expected to pursue restoration of the subsidies, changes to the work requirements, and, longer term, long-term care coverage under Medicare. President Trump retains veto power, and the new Congress does not take office until January. (Link)

Healthcare News and Deals

  1. Bertram Capital agrees to acquire Medical Technology Associates, a medical equipment and compliance services provider, for $400 million to $450 million. MTA, based in Pinellas Park, Florida and previously backed by Riverarch Equity Partners, provides medical gas testing and inspection, biomedical equipment service, calibration, and cleanroom and hood certification for healthcare facilities. The company was marketed at slightly more than $20 million of EBITDA. The sale is a full exit for Riverarch and hands Bertram a national compliance and equipment-service platform serving hospitals and other healthcare facilities. (Link)
  2. Charles River Laboratories (NYSE: CRL) agrees to acquire Frontage’s bioanalysis and DMPK businesses in Exton, Pennsylvania for approximately $470 million, plus up to $75 million of contingent consideration. Charles River will acquire Frontage Holdings’ bioanalysis and drug-metabolism and pharmacokinetics operations, including a CLIA-certified central laboratory. The two Exton sites cover about 150,000 square feet and employ approximately 340 people. The businesses represented about 40% of Frontage’s 2025 revenue of $256.7 million. Closing is expected in the first half of 2027, subject to shareholder and regulatory approvals. (Link)
  3. CorMedix Therapeutics (NASD: CRMD) agrees to acquire substantially all assets of Heron Therapeutics (NASD: HRTX) for approximately $223 million upfront, plus up to $55 million in earn-outs, adding four commercial-stage acute care and oncology products. Upfront consideration is $145 million in cash plus 14,583,333 CorMedix shares valued at about $77.6 million, for an aggregate of approximately $222.6 million, plus up to $55 million tied to ZYNRELEF net sales in 2028. The assets include ZYNRELEF, APONVIE, CINVANTI and SUSTOL, with trailing twelve-month net product revenue of about $150 million. Heron remains publicly traded. The deal is expected to close in the first quarter of 2027, subject to Heron stockholder approval and HSR clearance. (Link)
  4. Vantive, backed by Carlyle, agrees to sell most of its hemodialysis business to Rockwell Medical (NASD: RMTI) for $125 million, plus up to $45 million of contingent consideration. The base purchase price is $125 million, subject to customary adjustments, with up to $45 million of additional contingent consideration based on revenue and EBITDA milestones. Rockwell will acquire hemodialysis concentrates, HD monitors including the AK 98, water treatment systems, related consumables and technical services, and Vantive’s manufacturing facility in Medolla, Italy. Vantive’s dialyzer portfolio, including Theranova, is not included. The sale concentrates Vantive on its remaining dialysis portfolio while giving Rockwell an integrated hemodialysis manufacturing and service footprint. (Link)
  5. VisiQuate, backed by Accel-KKR, acquires Finvi’s Artiva HCx business, adding revenue cycle workflow execution to its analytics platform. Artiva HCx routes and runs insurance follow-up, denial management and collections work. VisiQuate partnered with Accel-KKR in 2024. The combination pairs VisiQuate’s revenue cycle analytics and automation with Artiva’s workflow orchestration, letting the combined platform move from identifying leakage to executing the follow-up work. Finvi is concentrating its resources on the third-party collections market it has served for nearly 50 years. HCx customers will be supported jointly by both companies during the transition. (Link)
  6. LeanTaaS acquires LookDeep Health to add ambient computer vision to its hospital operations platform used by nearly 200 health systems. LeanTaaS’s capacity and patient-flow software is used by nearly 200 health systems in more than 1,200 hospitals. LookDeep brings computer vision monitoring that has been evaluated in peer-reviewed research, with reported fall-rate reductions of more than 70% and an 80% drop in medication errors across deployments. The company also launched iQueue for Virtual Care, which bundles virtual observation, virtual nursing and virtual medicine. LookDeep co-founder Narinder Singh joins as SVP of ambient intelligence. This is LeanTaaS’s second acquisition in about two months, following its purchase of care-transition platform Aidin. (Link)
  7. Ellipsis Health acquires Kouper Health, combining vocal AI care management with native EHR navigation for health plans and health systems. Ellipsis’s Sage AI Care Manager is used by seven of the top 20 U.S. health plans and leading academic medical centers. Kouper, founded in 2022, builds AI agents that embed in health-system workflows for patient navigation, scheduling and post-discharge follow-up. It has raised funding from General Catalyst, 25Madison and CVS Health Ventures. Kouper’s team is joining Ellipsis, and both brands will continue to serve existing customers while the companies develop a combined product roadmap. The combination pairs Ellipsis’s vocal AI with Kouper’s ability to act inside the EHR. (Link)
  8. Porter, backed by Eir Partners, acquires Pareto Intelligence, uniting analytics, engagement and care delivery for Medicare, Medicaid and ACA health plans. Pareto provides clinical, quality and risk analytics that help health plans identify member needs across a population. Its population intelligence will be integrated into Porter’s technology, engagement and care delivery platform for Medicare, Medicaid and ACA health plans. Brandon Solomon, who led Pareto as General Manager, joins Porter as Chief Commercial Officer. The deal gives Porter an in-house analytics layer rather than a third-party data feed. (Link)
  9. Discovery Senior Living acquires management agreements for 26 senior living communities from Senior Solutions Management Group, adding more than 2,200 units. The portfolio covers more than 2,200 units across eight states in the South and Southeast (approximately 69% assisted living, 18% independent living and 13% memory care). Current property owners retain ownership of the communities. The agreements became effective November 1. Discovery is the largest U.S. senior living operator, with more than 50,000 units across roughly 446 communities. The transaction expands Discovery’s management footprint without taking on real estate ownership. (Link)
  10. CommonSpirit Health signs a definitive agreement to sell three North Dakota hospitals to Altru Health System, following a letter of intent announced earlier this year. The facilities are CHI St. Alexius Health Bismarck, a 157-bed acute-care hospital, and two critical-access hospitals in Turtle Lake and Garrison. The agreement follows a non-binding letter of intent announced earlier this year and ten months of due diligence. Altru already acquired CHI St. Alexius Health Devils Lake from CommonSpirit in 2025. The three hospitals will retain their Catholic affiliation. The definitive agreement converts the earlier letter of intent into a signed transaction after regulatory and operational review. (Link)
  11. LUX Infusion, backed by Frazier Healthcare Partners, acquires the specialty infusion business of Be Well Memory and Infusion, adding ambulatory infusion centers in Lincoln and Omaha. LUX Infusion is a clinician-led infusion service network. The acquisition adds established teams and two ambulatory infusion centers in Nebraska to its national footprint. The company plans to introduce home infusion services for eligible patients in those markets. Be Well’s specialty infusion business offers FDA-approved infusion treatments for early Alzheimer’s disease and other complex therapies. The add-on is LUX’s latest expansion under Frazier ownership. (Link)
  12. Integrated Home Care Services agrees to combine with CareCentrix, previously owned by Sycamore Partners, to form a national in-home benefit management platform. CareCentrix provides specialty benefit management for home nursing, durable medical equipment, home infusion and sleep diagnostics, and coordinates care for more than 22 million members. The combined organization will be headquartered in Miramar, Florida. Christopher Bradbury will serve as CEO and Haley Sofiane as President and COO. Until closing, the two companies will continue to operate independently. The combination creates a single platform spanning home-based benefit management for health plans. (Link)
  13. KKR, Hildred Capital and EQT Life Sciences merge Sapphiros and binx health to form Onvaro, a next-generation point-of-care diagnostics company. Onvaro pairs binx’s FDA-cleared, CLIA-waived point-of-care platform with Sapphiros’s printed-electronics and blood-collection technology. Mike Karsonovich, who has led binx, will serve as CEO. KKR, Hildred and EQT Life Sciences are investing additional capital to support the combined company. The merger brings a cleared diagnostic platform together with device and collection technology under one PE-backed entity. (Link)
  14. PRISM Vision Group acquires Spectrum Vision Partners, an ophthalmology practice management organization that supports more than 150 independent eye care providers. Spectrum supports 58 ophthalmology sites of care and five ambulatory surgery centers across New York, Pennsylvania, Connecticut, New Jersey and West Virginia. It was previously backed by Apogem Capital and Blue Sea Capital. PRISM is a physician-led ophthalmology and retina administrative services organization with more than 90 locations and eight ASCs. Spectrum-supported practices will retain physician-led governance while gaining access to PRISM’s operational and research infrastructure. (Link)
  15. Elevate Dental Partners acquires Compass Dental Services, a seven-location dental group with 91 operatories in North Central Texas. Compass was built by brothers Dr. Scott Ballard and Dr. David Ballard over more than two decades. It has 91 operatories across North Central Texas. The Ballards will remain in leadership roles and become shareholders in Elevate. Partner dentists will continue to lead their practices. Elevate, founded in 2019, is a dental partnership organization that provides practice management and non-clinical support. The deal is Elevate’s first transaction of 2026 and establishes its operating presence in Texas. (Link)
  16. argenx (Euronext & NASD: ARGX) agrees to acquire Unnatural Products for up to $1.15 billion, adding an AI-guided macrocyclic peptide discovery platform.Unnatural Products, based in Santa Cruz, California, develops orally delivered macrocyclic peptides aimed at targets that conventional drugs struggle to reach. Its platform pairs AI-guided design with massively parallel synthesis. The deal is $550 million in cash upfront plus up to about $595 million tied to development and regulatory milestones. argenx already held a minority stake from a multi-target collaboration. UNP, founded in 2016, employs more than 50 people and will continue operating from Santa Cruz as argenx’s dedicated peptide discovery hub. The acquisition gives argenx a dedicated discovery engine for hard-to-drug targets rather than a single asset. (Link)
  17. Cinven agrees to acquire Theramex, a London-based women’s health specialty pharmaceutical company, from Carlyle and PAI Partners in a deal valued at about €2.6 billion. Theramex develops, licenses and sells treatments across menopause, osteoporosis, contraception and fertility. It has more than 500 employees and serves patients in more than 80 countries. Its treatments have reached more than six million women. Carlyle and PAI acquired the business in 2022 for roughly €1.4 billion and say they more than doubled EBITDA during their hold. Cinven plans to expand Theramex’s geographic footprint and pursue in-licensing deals. Closing is expected in the first half of 2027, subject to regulatory approval. (Link)
  18. ANI Pharmaceuticals launches a $560 million recommended cash offer for Sweden’s Egetis Therapeutics. The offer is SEK 11.25 per share in cash, plus cash for outstanding convertibles and warrants, for a total value of approximately SEK 5.3 billion, or about $560 million. The Egetis board unanimously recommended acceptance. Shareholders representing about 42% of outstanding shares have entered into undertakings to accept, subject to certain conditions. The offer represents a 12.6% premium to the prior closing price and a 27% premium to the 60-day volume-weighted average. The acceptance period is expected to run from around November 20 to December 18, 2026. Egetis is a rare-disease company focused on metabolic and endocrine disorders. (Link)
  19. Omega Healthcare Investors and Foundation Partners acquire U.K. care home operator Runwood Homes for £615 million. The portfolio comprises 55 care homes. Upon completion, Runwood will be managed by Evera Living, Foundation Partners’ care platform, led by newly appointed CEO John Forrest, formerly COO of Spire Healthcare. The deal takes Omega’s U.K. portfolio to more than 350 care homes. Omega last year bought a portfolio of 46 care homes from Four Seasons Health Care Group for £241 million. The transaction expands Omega’s U.K. care-home exposure under Foundation Partners’ operating platform. (Link)
  20. Lonza agrees to buy five U.S. CDMO sites from Merck KGaA, more than doubling its U.S. manufacturing footprint. The enterprise valuation is in the low- to mid-triple-digit millions of Swiss francs. The sites are in St. Louis (bioconjugates), Madison and Verona, Wisconsin (high-potency payload-linkers), Carlsbad, California (viral vectors) and Indianapolis (lipid nanoparticles and liposomes). The acquisition adds approximately 1,100 employees and expands Lonza’s U.S. CDMO footprint from four to nine sites. Lonza expects the sites to generate about 250 million Swiss francs in annual sales by 2028. The sites cover modalities Lonza did not previously manufacture in the United States at this scale. (Link)
  21. EQWAL Group acquires Lerman & Son Orthotics and Prosthetics, a Beverly Hills clinic with particular experience in pediatric care. Lerman & Son was founded in 1915 and has operated in Los Angeles since 1948. It is managed by Jack Schwartz, Denise Leiter and Larry Lerman, employs about 30 people, and has particular experience in pediatric orthotics and prosthetics. EQWAL is a France-based global orthotics and prosthetics provider. The acquisition adds a U.S. patient-care location to its network and continues EQWAL’s series of U.S. clinic acquisitions. (Link)
  22. Sunrise Medical, backed by Platinum Equity, acquires Spinergy, a San Marcos, Calif. maker of wheelchair wheels and carbon-fiber components. Spinergy has been in business for more than three decades, and more than 90% of world-class wheelchair athletes choose its wheels for their primary sport chairs. Spinergy will continue to operate independently within the Sunrise group, retaining its brand, organization and team. Sunrise will support growth through product development, customer support and broader market reach. The acquisition adds a specialized wheel and component brand to Sunrise’s mobility portfolio under Platinum Equity. (Link)
  23. Waters acquires venture-backed MOBILion Systems, adding SLIM ion-mobility separation to its mass spectrometry platform. SLIM separates molecules by size, shape and charge in milliseconds, resolving differences that are difficult to distinguish using liquid chromatography and mass spectrometry alone. Waters is pairing the technology with its Xevo MRT mass spectrometry platform to expand its entry into the proteomics market, which the company sizes at about $2 billion. The acquisition is intended to increase proteome coverage, sensitivity and throughput for complex biological samples. MOBILion was venture-backed prior to the sale. (Link)
  24. Confluent Medical Technologies acquires Northern Nitinol, a Minnesota-based maker of Nitinol components for medical devices. Northern Nitinol specializes in rapid prototyping and Nitinol design and processing. Founder and President Mike Davis built the company over 11 years. The acquisition adds a Nitinol-focused facility in Minneapolis to Confluent’s Nitinol Center of Excellence in Fremont, California. Confluent is a contract manufacturer of Nitinol and polymer components for medical devices. The add-on expands Confluent’s prototyping capacity for device OEM customers. (Link)
  25. Standard Dental Labs (OTCQB: TUTH) acquires the assets of M&D Dental Arts, a Deltona, Florida dental laboratory, expected to double its Orlando output. The acquisition includes M&D’s client base and accounts receivable. The work will transition into Standard’s Orlando facility and is expected to double that laboratory’s current production output. M&D’s existing staff will not transfer. Standard also said its internally developed Bridge AI software, a CRM and digital workflow platform, is in live testing with a company-wide launch targeted for December 1. The deal adds volume to Standard’s existing Florida laboratory rather than a new facility. (Link)
  26. Globus Medical (NYSE: GMED) acquires Synaptive Medical, a cranial neurosurgery technology company, through a court-appointed receivership process. Synaptive develops surgical visualization, navigation, planning and MRI tools for complex cranial procedures. The acquisition closed on August 4, 2026, and Globus announced it on November 3. Globus plans to combine Synaptive’s technology with its Excelsius ecosystem to build integrated procedural solutions for neurosurgeons. The company’s immediate priority is continuity for Synaptive customers and service for the installed base. The delayed announcement reflects the receivership process rather than a newly signed agreement. (Link)
  27. Animal Outpatient Specialty Network, backed by Percheron Capital, acquires a portfolio of outpatient veterinary specialty practices, becoming the largest dedicated outpatient specialty network. The acquired portfolio includes clinics under the Arizona Veterinary Dental Specialists, Dentistry and Oral Surgery for Animals, Dermatology for Animals, Eye Care for Animals and Veterinary Cancer Group brands. The acquisition establishes AOSN as the nation’s largest dedicated outpatient veterinary specialty business, with more than 300 veterinary specialists and residents. AOSN’s network spans dentistry, dermatology, internal medicine, oncology, ophthalmology and surgery. The deal consolidates several specialty brands under one Percheron-backed platform. (Link)
  28. iSpecimen (NASD: ISPC) acquires two AI products from Foldlab AI for up to $4.5 million. The products are an AI agent that identifies disease-associated proteins and a model that predicts and monitors disease trends. The price is $750,000 in cash at closing, up to $1.25 million in milestone payments, and the balance in restricted stock. iSpecimen is an online marketplace connecting researchers who need biospecimens with healthcare specimen providers. The acquisition was completed on November 2 under an asset purchase agreement dated September 4. The tools are intended to help researchers identify and source relevant biospecimens more efficiently. (Link)

Venture Deals and Other

  1. GE HealthCare leads Laza Medical’s up to $160 million Series B structured financing to advance intelligent imaging for the cardiac catheterization lab.Laza is a Shifamed portfolio company developing AI-powered robotic imaging for cardiac interventions. Returning investors and new participants joined GE HealthCare in the round. The financing will support development of an intelligent imaging system for the cardiac catheterization lab. The structure includes tranches tied to development milestones. (Link)
  2. Viking Global Investors leads nPhase’s $30 million Series D to scale its AI-native clinical data platform. The round is nPhase’s first equity raise since 2017. Proceeds will scale its clinical data platform for life sciences customers and support global expansion. The platform is designed to unify clinical trial data and reduce the time from data capture to analysis. (Link)
  3. Viking Global Investors leads Nova Anchora’s $23 million equity financing to advance a topical collagen VII therapy for dystrophic epidermolysis bullosa. Nova Anchora is developing a topical protein therapy for dystrophic epidermolysis bullosa. Venture philanthropy and existing backers participated alongside Viking. The round includes an initial tranche and additional capital tied to development milestones. Proceeds will advance the topical collagen VII program toward clinical development. (Link)
  4. Medicus Pharma (NASD: MDCX) signs a non-binding letter of intent for a proposed SPAC combination of its SkinJect subsidiary at a $135 million pre-money valuation. SkinJect is developing a dissolvable microneedle patch for basal cell carcinoma lesions, focused on Gorlin syndrome. The LOI contemplates concurrent financing for the SKNJCT-005 study. The combination remains non-binding and is subject to definitive documentation and closing conditions. (Link)
  5. HealthEdge Investment Partners completes a majority investment in The Columbus Organization, acquiring its stake from CareSource, which retains a minority interest. Columbus, founded in 1984 and based in Blue Bell, Pennsylvania, provides care management, clinical staffing and quality-improvement services for people with intellectual and developmental disabilities and aging-related needs. HealthEdge previously owned the company from 2016 to 2021 and completed 10 add-on acquisitions during that period. CareSource retains a minority interest. The deal returns Columbus to a sponsor HealthEdge knows from its prior hold. (Link)
  6. Linden Capital Partners makes a strategic growth investment in AnewHealth, joining existing backers Nautic Partners and Vistria. Linden and Nautic will jointly govern the company, and President and CEO Brian Adams and his management team will stay in place. The Vistria Group remains an existing investor. AnewHealth now serves more than 160,000 patients on pharmacy services, up nearly 50% over the past two years. It works with value-based care organizations, including PACE programs. The investment supports continued scaling of AnewHealth’s pharmacy services platform. (Link)
  7. Equity Medical acquires a majority stake in Skylight Health Research, expanding its clinical research site network into New England and the Mountain West. Skylight operates clinical research sites in Burlington, Massachusetts and Colorado Springs, Colorado. Both sites will transition to the Equity Medical brand under their existing clinical leadership, with Alisha Garibaldi continuing to oversee the sites. The combined network now spans eight locations across five states. The deal deepens Equity Medical’s therapeutic range into cardiometabolic, rheumatology, pain and vaccine research. (Link)
  8. Curewell Capital acquires a majority stake in ECA Medical, a maker of single-use instruments and procedural kits for medical device OEMs, from LongueVue Capital. ECA, founded in 1979 and based in Thousand Oaks, California, has shipped more than 55 million instruments and 500,000 procedural kits. It operates five FDA-registered, ISO 13485-certified facilities in California and Utah. President and CEO Lane Hale and the management team will stay in place. Curewell’s capital is intended to fund expansion of ECA’s product portfolio and manufacturing capacity. The deal is a sponsor-to-sponsor transfer from LongueVue. (Link)
  9. CVS Health (NYSE: CVS) announces intent to separate into two independent public companies by the first half of 2028. One company, to be called CVS Pharmacy, will comprise approximately 9,000 retail pharmacies, mail-order pharmacy, MinuteClinic and the Health100 technology services business. The other, retaining the CVS Health name in the interim, will comprise Aetna, CVS Caremark, CVS Specialty, Oak Street Health and Signify Health. The separation is intended to be tax-free to CVS Health and its shareholders. Both companies are expected to have investment-grade ratings at the time of separation. The decision follows a strategic review by the board. The split would separate the retail pharmacy and the insurance and care-delivery businesses. (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update November 2nd, 2026

Healthcare Weekly News and Deals

  1. Ferring Pharmaceuticals agrees to acquire Insight Partners-backed Gameto for up to $1.38 billion, adding Fertilo, stem cell-based IVF platform, to its reproductive medicine portfolio. Privately held Swiss drugmaker Ferring Pharmaceuticals signed an agreement to acquire Gameto in a deal valued at up to $1.3825 billion. The companies did not say how the price splits between upfront and contingent payments. The total depends on development, regulatory and commercial milestones, and the two will operate independently until closing. Gameto has raised about $127 million since its 2020 founding from backers including Insight Partners. At the full headline value, that is a return of roughly 11x paid-in capital. Fertilo uses stem cell-derived ovarian support cells to mature eggs outside the body, which could shorten IVF cycles to about three days. It is cleared in Australia and parts of Latin America and is in U.S. Phase 3 testing. (Link)
  2. RadNet (NASDAQ: RDNT) agrees to acquire Housatonic Partners-backed ONRAD for $350 million in cash, 5 million shares and an earnout of up to $210 million, entering hospital-based teleradiology. RadNet (NASDAQ: RDNT) signed a definitive agreement on October 26 to buy ONRAD, a teleradiology and in-hospital radiology staffing provider owned by Housatonic Partners. ONRAD shareholders receive $350 million in cash and 5 million RadNet shares at closing. An earnout of up to $210 million is tied to 2027 EBITDA and is payable in cash or stock at RadNet’s election. ONRAD supports more than 225 hospital facilities in 26 states through over 130 contracted radiologists. It has grown revenue 10–20% annually with Adjusted EBITDA margins above 30%. RadNet expects $190–200 million of revenue and $60–65 million of Adjusted EBITDA in year one. ONRAD will anchor a new Radiology Professional Services segment, and closing is expected in early 2027. (Link)
  3. Merit Medical Systems (NASDAQ: MMSI) acquires the remaining ~82% of Solo Pace for about $45 million, adding TAVR temporary pacing systems to its cardiac therapies platform. Merit Medical Systems (NASDAQ: MMSI) disclosed on October 30 that it had bought all remaining equity in Minneapolis-based Solo Pace on October 13, for purchase consideration of about $45 million. The deal turns a staged strategic investment into full ownership. Between January 2023 and December 2025, Merit paid $5 million for roughly 18% of Solo Pace, an option to buy the rest on commercialization milestones, and exclusive distribution rights. Solo Pace makes the SOLO PACE CONTROL and FUSION temporary pacing systems for TAVR and other transcatheter valve procedures. (Link)
  4. Privia Health (NASDAQ: PRVA) acquires the American Choice Healthcare MSSP business from Cano Health for about $36 million, adding 36,000 attributed lives to its value-based footprint. Privia Health, based in Arlington, Virginia, is a national physician-enablement company that organizes independent practices into value-based networks. It works with more than 5,000 providers across roughly 1,300 practices in 24 states, supporting more than 5 million patients. Its ACOs, operating under Privia Care Partners, generated $233 million in shared savings in the 2024 Medicare Shared Savings Program year. American Choice Healthcare was the MSSP subsidiary of Cano Health, a Florida-based senior primary care company that went through Chapter 11 in 2024 and emerged private. The ACO joins Privia Care Partners and will care for more than 36,000 Medicare lives starting in 2027. (Link)
  5. Davion Healthcare (NASDAQ: DAVI) agrees to acquire Philadelphia’s Healthcare Stat Homecare for $13.5 million in cash and stock, the first in a planned series of acquisitions of profitable healthcare businesses. Dublin-based Davion Healthcare (NASDAQ: DAVI), a developer of non-invasive health monitoring technologies, agreed on October 27 to buy Healthcare Stat Homecare (HSH), a Philadelphia home health provider. The $13.5 million price comprises $8 million in cash and $5.5 million in Davion shares at an agreed $13 per share. HSH reported about $11.6 million of 2025 gross receipts and $1.9 million of ordinary business income, both unaudited. That implies roughly 1.2x receipts and 7x income. HSH provides skilled nursing, home health aide and rehabilitation services and is Medicare and Medicaid certified. Davion calls it the first of a year-long program to acquire profitable healthcare businesses, with completion expected by December 31, 2026. (Link)
  6. Pelthos Therapeutics (NYSE American: PTHS) to combine with Castle Creek Biosciences in an all-stock merger worth 5.2 million shares upfront, plus up to 5.8 million contingent shares and $300 million in milestones. Durham, North Carolina-based Pelthos Therapeutics (NYSE American: PTHS) agreed on October 30 to merge with Exton, Pennsylvania-based Castle Creek Biosciences. Castle Creek shareholders receive 5.2 million Pelthos shares at closing, about 32.5% of fully diluted shares. They can also receive up to 5.8 million more shares on FDA approval of D-Fi, and up to $300 million in cash milestones, including $50 million on hitting Phase 3 endpoints. They also get 80% of the proceeds from any priority review voucher. D-Fi is a redosable gene-modified cell therapy for dystrophic epidermolysis bullosa. It holds Orphan Drug, Fast Track and RMAT designations, with a continued Phase 3 study planned. Castle Creek gets two of ten board seats, and closing is expected by the end of the first quarter of 2027. (Link)
  7. Leonard Green & Partners acquires Radon Medical Imaging, a West Virginia imaging equipment service organization, from 5th Century Partners. Los Angeles-based Leonard Green & Partners bought Radon Medical Imaging from 5th Century Partners (5CP) on October 27; terms were not disclosed. Radon was founded in 1976 and is based in Charleston, West Virginia. It is an independent service organization that services, repairs and sells new and refurbished imaging equipment, including MRI, PET/CT, mammography, cath lab, C-arm and X-ray systems. Its customers are hospitals, clinics and outpatient facilities. Radon expanded from five states to 26, grew past 220 employees and completed four add-ons: Premier Imaging, Tristate Biomedical, Alpha Imaging and Majestic Medical Solutions. Leonard Green gets a scaled platform in a fragmented imaging-service market. (Link)
  8. Mainsail Partners-backed ChiroHD acquires ChiroBilling, adding native billing and revenue cycle management to its chiropractic EHR platform serving more than 2,000 clinics. Atlanta-based ChiroHD announced on October 22 that it had acquired ChiroBilling, an outsourced chiropractic billing company with a 30-person team; terms were not disclosed. Growth equity firm Mainsail Partners, which invests in bootstrapped B2B software companies, put $26 million into ChiroHD in April 2025 to fund AI-led product development and customer support. The deal adds an established revenue cycle team and its customers instead of building billing in-house. The two companies already jointly serve more than 100 clinics. ChiroBilling CEO Shannon Berg becomes president of a new ChiroBilling division. The rationale is collections leakage: chiropractors collected about 62 cents per billed dollar in 2025, down from 71 cents. (Link)
  9. Ares Management (NYSE: ARES)-backed Duly Health and Care acquires Fox Valley Imaging, an independent outpatient imaging center in Naperville, Illinois. Duly Health and Care acquired Fox Valley Imaging, according to an October 27 release; terms were not disclosed. Duly is the Downers Grove, Illinois multispecialty physician group owned by Ares Management (NYSE: ARES) and Athyrium Capital Management since 2017. Fox Valley has served Naperville for more than 30 years with MRI, MRA, CT, ultrasound, echocardiography, video fluoroscopy and X-ray. Duly plans to add mammography and DEXA at the site. That expands its outpatient imaging network in Chicago’s western suburbs and keeps more ancillary imaging volume inside its own system. Duly has more than 1,000 primary and specialty care providers across 150+ locations. The add-on extends Ares’ buy-and-build of one of the largest independent physician groups in the Midwest. (Link)
  10. Platform Partners-backed Principle Health Systems acquires mobile imaging assets in the St. Louis market, extending bedside diagnostics for long-term care facilities into Missouri and Illinois. Houston-based Principle Health Systems announced on October 30 that it had acquired select assets of an unnamed mobile diagnostic imaging company serving greater St. Louis; terms were not disclosed. Houston private investment firm Platform Partners invested in Principle in January 2023, with the founders keeping majority ownership. The deal brings imaging technologists, mobile equipment and established facility relationships. It adds bedside X-ray, ultrasound and EKG for long-term care operators in Missouri and Illinois. It follows a string of add-ons under Platform Partners: BioStat Laboratory in 2023, BioStat Imaging and Telos PGX in 2024, and Heartland Health Laboratory in 2025, plus a June 2026 asset purchase. Together they build a single-source mobile lab and imaging platform for long-term care. (Link)
  11. HealthEdge Investment Partners-backed Western Microsurgical acquires Q Surgical and Proficient Surgical, expanding its surgical microscope platform to 18 states. Denver-based Western Microsurgical (WMS), a HealthEdge Investment Partners portfolio company, announced two acquisitions on October 27; terms were not disclosed. Q Surgical serves hospitals and ASCs in Northern California and Nevada, and Proficient Surgical serves the Northeast. The owners of both sellers rolled meaningful equity into the combined company and stay active in operations. WMS is an independent manufacturer’s representative and service organization for Leica Microsystems. It also took over a Leica sales and service contract previously held by Shawnee Medical in two states. The combined business now covers 18 states. That advances HealthEdge’s plan to build a national surgical microscopy platform through partnerships with experienced regional operators. (Link)
  12. Svoboda Capital Partners partners with 120/80 Health Group, a founder-led healthcare and life sciences communications consultancy. 120/80 Health Group, founded in 2018, started as a digital health communications firm and has grown into a strategic consultancy for healthcare and life sciences. In 2024 it restructured as a holding company with two brands: 120/80, focused on digital health, and AOx3, based in Silicon Valley and New York, for companies applying technology and AI to health. Svoboda Capital Partners, founded in 1998, is a lower-middle-market private equity firm focused on professional services, industrial and commercial services, and transportation. The partnership lets 120/80 reinvest in its team and expand its service offerings. Prosper Group advised 120/80. (Link)
  13. GrowthCurve Capital makes a majority investment in TailorMed, the medication access and affordability platform spanning 950 hospitals and 4,700 clinics. TailorMed connects patients, providers, pharmacies and life sciences companies across more than 3,100 pharmacies and 6,000 support programs. It has supported 75 million patients and secured $7.4 billion in financial assistance since 2020. The capital will fund product work and expansion of its AI-powered solutions. Leerink Partners and TripleTree advised. (Link)
  14. InTandem Capital Partners completes a strategic growth investment in Atlas Health, the AI-powered patient affordability platform for hospitals and health systems. New York-based healthcare investor InTandem Capital Partners closed a growth investment in Atlas Health on October 29; terms were not disclosed. Founder and CEO Ethan Davidoff and the management team stay on as significant shareholders. Atlas was founded in 2017. It uses its agentic AI, Ava, and EHR integrations to match and enroll patients in coverage and financial assistance programs, which raises reimbursement and cuts uncompensated care for providers. InTandem’s thesis is that patient affordability is moving from a back-office task to a front-line revenue recovery tool as coverage erodes and specialty drug costs climb. The capital will fund product initiatives and expansion into specialty pharmacies. It follows InTandem’s December 2025 investment in The Phia Group. (Link)
  15. GTCR- and Heritage Group-backed Equiti acquires Lexi AI, pairing healthcare AI interpretation with its Martti human medical interpreter network. Equiti, the Sunrise, Florida-based healthcare language access company, acquired Lexi AI on October 28; terms were not disclosed. GTCR, with Heritage Group and lender Monroe Capital, bought the business from UpHealth for $180 million in November 2023. It was then combined with Voyce and rebranded as Equiti. Lexi was founded by Linh Pham and Siddharth UR and won the 2025 Harvard Business School New Venture Competition social enterprise grand prize. It provides AI interpretation in more than 35 languages, with EHR and phone integrations. Equiti’s Martti platform offers 24/7 qualified medical interpreters in 250+ languages. The add-on gives the sponsors an AI tier to sell alongside human interpretation. (Link)
  16. The Riverside Company adds CSB Nutrition to its Western Botanicals / WB Blends supplements manufacturing platform, expanding capsule and powder capacity. Western Botanicals is a vitamins, minerals, and supplements contract manufacturer founded in 1996. It has more than 200 employees and over 200,000 square feet across three facilities, and its products are sold through channels including Walmart, Amazon, Target, Vitamin Shoppe, and Costco. The Riverside Company acquired it in February 2026 and later added Yellow Emperor, a liquid specialist. CSB Nutrition, also based in Spanish Fork and founded in 2001 by Al Call, Craig Shields, and Jeff Bancroft, is a full-service VMS CDMO with roughly 60 to 200 employees and a cGMP, NSF-certified, FDA-registered facility of more than 100,000 square feet. It serves major VMS brands and also works in sports nutrition, personal care, and pet care. Together with WB Blends and Yellow Emperor, the platform now covers capsules, powders, and liquids in one place, including stick packs and gusseted bags. Riverside has made more than 40 platform investments under its health, longevity, and flavor thesis. (Link)
  17. US WorldMeds acquires Orbus Therapeutics, backed by Longitude Capital, H.I.G. HealthBridge, Abingworth, Adams Street Partners and Agent Capital, to advance eflornithine in recurrent Grade 3 astrocytoma. Louisville, Kentucky-based US WorldMeds acquired Menlo Park, California-based Orbus Therapeutics on October 27. It made an undisclosed upfront payment, with development, regulatory and sales milestones plus tiered U.S. royalties to follow. That gives Orbus’s investors an exit with continued upside: Longitude Capital, H.I.G. HealthBridge, Abingworth, Adams Street Partners and Agent Capital. In the Phase 3 STELLAR trial, Orbus’s oral eflornithine missed its primary overall-survival endpoint across all patients. However, a subset defined before unblinding, patients with IDH-mutant Grade 3 astrocytoma, showed median overall survival of 34.9 months versus 23.5 months. The program holds FDA Breakthrough Therapy designation. US WorldMeds already markets eflornithine as IWILFIN for high-risk neuroblastoma and plans to discuss a path forward with the FDA. (Link)
  18. Water Street Healthcare Partners- and JLL Partners-backed EVERSANA acquires Estima Scientific, adding AI-powered health economics and outcomes research tools to its life sciences commercialization platform. Estima, a London firm founded in 2019, pairs specialist consulting with proprietary generative-AI applications for economic modeling, systematic literature reviews and network meta-analysis. Its tools have been used by large pharma and by the U.K.’s NICE. EVERSANA will fold the capability into its market access and value-and-evidence offerings; co-founders Tim Reason and Andy Gimblett join the EVERSANA team. (Link)
  19. Azenta (NASDAQ: AZTA) acquires SynPlexity and signs an exclusive license with Elegen to expand its GENEWIZ gene synthesis business. Burlington, Massachusetts-based Azenta (NASDAQ: AZTA) announced two deals on October 30; terms were not disclosed. It acquired SynPlexity, a synthetic biology company that makes high-throughput pooled gene libraries, and signed an exclusive license for Elegen’s cell-free DNA manufacturing platform. SynPlexity’s pooled assembly technology produces thousands of full-length gene variants in a single library. That lets researchers build and test large numbers of candidates, including AI-generated designs. Elegen’s platform aims for higher DNA quality, faster delivery and compact production lines that can be sited near customers. Both strengthen GENEWIZ, Azenta’s sequencing and gene synthesis unit, in synthetic biology, protein engineering and AI-enabled drug discovery. Azenta will give more detail on its fiscal Q4 2026 earnings call. (Link)
  20. Peak Rock Capital-backed HuFriedyGroup signs an agreement to acquire the dental business of Italy’s Mectron, adding piezoelectric surgery, ultrasonic scaling and air-polishing systems to its global dental portfolio. HuFriedyGroup is a global maker of dental instruments, infection prevention products, and instrument management systems. Founded in 1908, it has roughly 1,500 employees, more than 10,000 products, and distribution in about 100 countries under brands including Hu-Friedy, Crosstex, Omnia, Accutron, and SS White. Peak Rock acquired it from Steris in 2024 for roughly $788 million. Mectron, founded in 1979 in Carasco, Italy, pioneered piezoelectric bone surgery with the launch of PIEZOSURGERY in 2001. It has about 250 employees and operates in more than 70 countries. The deal covers Mectron’s dental operations in Italy, the non-medical activities of its German subsidiary, and the dental activities of Piezosurgery Inc. in Columbus, Ohio. Mectron keeps its medical business. Manufacturing stays in Carasco under a multi-year supply agreement, so HuFriedyGroup gains the technology and commercial reach without disrupting production. (Link)
  21. NeckWise acquires Western Carolina Chiropractic, adding an Asheville practice to its upper cervical chiropractic network. NeckWise is a growing multi-state network of upper cervical chiropractic offices founded in 2024 by Dr. Drew Hall, Dr. Matt Morris, and Dr. Rusty Lavender. The group focuses exclusively on the atlas (C1) and axis (C2) vertebrae, using in-office cone beam CT imaging and gentle, no-twist adjustments rather than traditional full-spine manipulation. It has offices across Florida, including the Tampa Bay area, Sarasota, Fort Myers, and Riverview, and in the Salt Lake City area of Utah. The Asheville practice’s Dr. Michael DiNunzio stays on. The location will add in-office 3D cone beam imaging, consistent with NeckWise’s standard across its network. (Link)
  22. Baystate Health integrates Baystate Mercy Hospital and its affiliates into its system, adding a Springfield hospital and 45 medical group entities. Baystate Health is a not-for-profit integrated system serving more than 800,000 people across western Massachusetts. It has roughly 13,000 employees, five hospitals, and more than 900 beds, with roots dating to the founding of Springfield Hospital in 1883. Baystate Medical Center is a 780-bed academic medical center and a teaching site of UMass Chan Medical School. Mercy Medical Center, previously part of Trinity Health of New England, faced financial pressures that put its long-term viability at risk. The $300 million integration covers Baystate Mercy and its joint venture affiliates, along with 45 medical group entities. Emergency department staffing moves to Baystate’s board-certified faculty, and the Sister Caritas Cancer Center joins Baystate’s cancer program. The systems are also unifying on an Oracle Health EHR. (Link)
  23. PsychPlus acquires California-based Precision Psychiatric Services, adding more than 100 psychiatrists and hospital partnerships to its technology-enabled mental health platform. Houston-based PsychPlus announced on October 23 that it had acquired Precision Psychiatric Services, a physician-led psychiatric group founded in 2018; terms were not disclosed. Precision brings more than 100 psychiatrists and hospital partnerships across California. Its hybrid in-person and telepsychiatry model covers emergency departments, inpatient units, consultation-liaison, outpatient and addiction settings. The deal follows PsychPlus’s acquisition of digital therapeutics developer Koa Health. Together they form a roll-up spanning prevention through hospital-based care. PsychPlus already works with more than 200 hospital systems and reports reach of over 6 million people. (Link)

Venture Deals and Other

  1. Bristol Myers Squibb (NYSE: BMY) leads Pathos AI’s $237 million Series E at a roughly $3 billion post-money valuation, with existing investors participating. New York-based Pathos AI closed a $237 million Series E on October 23 at a post-money valuation of about $3 billion. Bristol Myers Squibb (NYSE: BMY) led and existing investors participated. BMS’s check comes with a strategic deal: non-exclusive access to Pathos’s Foundry agentic AI platform across its R&D portfolio, and three-year exclusive rights in neuroscience. Pathos will also license a neurological-disease dataset from Tempus AI (NASDAQ: TEM) under a five-year, $55 million agreement. Proceeds will scale Foundry and advance four clinical oncology assets. The priority is JSKN-016, a TROP2/HER3 bispecific ADC heading toward registrational studies. The others are pocenbrodib, AstraZeneca (NASDAQ: AZN)-partnered AZD4241 and MET inhibitor DO-2. (Link)
  2. Avego leads Opentrons Labworks’ $40 million Series E, with BroadOak Capital Partners participating, to scale lab robotics and AI-driven autonomous science. Opentrons Labworks raised a $40 million Series E on October 30. Healthcare investor Avego led, with additional investment from BroadOak Capital Partners; valuation was not disclosed. Opentrons has deployed more than 11,000 lab automation robots in over 80 countries to academic groups, diagnostic labs and global pharma companies. Avego’s thesis is that drug developers and AI companies are moving to automated workflows that generate machine-usable data, and that these workflows will converge on Opentrons’ platform. Proceeds will fund AI-driven experiment execution, faster protocol development, broader instrument capabilities, deeper integration with other lab-automation tools, and expansion into new markets. Earlier this year Opentrons began using Nvidia (NASDAQ: NVDA) Isaac and Cosmos to generate physical-AI training data. (Link)
  3. Threshold Ventures leads Vera Health’s $28.5 million Series A, with Mantis VC, SV Angel, Y Combinator and Gradient participating, bringing total funding to $32 million. San Francisco-based Vera Health announced a $28.5 million Series A on October 27 led by Threshold Ventures. New investors Mantis VC and SV Angel joined, and existing backers Y Combinator and Gradient tripled down, bringing total funding to $32 million. The investor case is capital efficiency. With 12 employees, Vera’s evidence-graded clinical decision support tool grew from a few thousand to more than 800,000 clinicians in 190 countries in a year, mostly through word of mouth. It has been the world’s most downloaded clinical app every month since June and reaches about one in four physicians in Spain and Italy. Funds will build evidence infrastructure, enter new markets and deepen medical-society partnerships such as ACEP. (Link)
  4. Metis MedTech leads StimCardio’s oversubscribed $30 million Series A, with Catalyst Health Ventures and corporate strategic investors participating, to fund a pivotal trial of its wearable atrial fibrillation therapy. StimCardio closed an oversubscribed $30 million Series A on October 29. It was led by Metis MedTech, the family office of John Slump, with Catalyst Health Ventures, several unnamed corporate strategic investors and new and existing backers participating. Slump’s prior exits include Farapulse and Atraverse Medical, more than $1.25 billion in combined deal value. He and Catalyst managing partner Joshua Phillips sit on the board. The round funds the NeuroPulse 2 pivotal study and an FDA De Novo submission for Rhyvive. Rhyvive is a wrist-worn nerve stimulator designed to reduce atrial fibrillation recurrence after catheter ablation, where 30–40% of patients relapse. It follows positive sham-controlled NeuroPulse 1 data published in Heart Rhythm. (Link)
  5. Valtruis leads Midstream Health’s $20 million Series A, with Andreessen Horowitz, Foundry and CommonSpirit Ventures participating, to scale AI financial operations for health systems. San Francisco-based Midstream Health raised a $20 million Series A on October 29 led by Valtruis. Andreessen Horowitz, Foundry and CommonSpirit Ventures continued to participate, bringing total funding to $29.2 million. Midstream’s AI agents check health-system contracts, claims, purchasing and pharmacy data against live transactions. They recover missed rebates, unenforced pricing terms and payer underpayments. Its customers represent more than $100 billion of annual operating expenses and over 250 hospitals. They include CommonSpirit Health, Mount Sinai and Houston Methodist, plus new clients Fairview Health Services and Keck Medicine of USC. Midstream has found 1,500+ recovery opportunities this year and is on pace for $100 million of client savings by year-end. (Link)
  6. Headline leads ClarityCare’s oversubscribed $16.5 million Series A, with Arthur Ventures, FJ Labs, Maverick, firstminute, Top Harvest Capital and Transpose Platform participating. ClarityCare announced an oversubscribed $16.5 million Series A on October 26, bringing total funding to nearly $20 million. Headline led, with new investors Arthur Ventures and FJ Labs and existing backers Maverick, firstminute, Top Harvest Capital and Transpose Platform. ClarityCare is an AI services company for health plans. Its Electra agent reviews authorization requests against clinical guidelines and member benefits and keeps a full audit trail. It can approve or escalate a request but never issues a denial, which reduces exposure as AI-driven denials draw scrutiny. Electra now handles requests end to end, from fax intake through case creation to outbound letters. The funding will go to hiring, new products and expansion into the government sector. (Link)
  7. Deerfield Management leads Setara Biosciences’ $90 million Series A, with Canaan, Droia Ventures, EcoR1, Euclidean Capital, Regeneron Ventures and Jazz Pharmaceuticals participating. Setara was formed after Jazz acquired Actio Biosciences for its lead epilepsy program. The new company takes the rest of Actio’s genetics-driven pipeline, led by the TRPV4 inhibitor STAR-0871 (formerly ABS-0871) for Charcot-Marie-Tooth type 2C and overactive bladder. David Goldstein, former Actio CEO, leads Setara. (Link)
  8. Camino Partners, founded by KIND Snacks founder Daniel Lubetzky, invests $62 million in Intake Breathing, the maker of a magnetic nasal dilator system. This is Intake’s first institutional capital and Camino’s largest investment. The Santa Barbara company has sold more than 100 million pairs of its breathing tabs and is approaching $100 million in annual revenue. Capital goes to team growth, retail expansion and scaling the consumer wellness brand. (Link)
  9. Viatris (NASDAQ: VTRS) launches its $36.50-per-share cash tender offer for Pacira BioSciences (NASDAQ: PCRX), valuing the non-opioid pain management company at about $1.46 billion. Viatris (NASDAQ: VTRS) started a cash tender offer on October 30, through its subsidiary Peach Purchaser Sub, for all outstanding shares of Pacira BioSciences (NASDAQ: PCRX). The price is $36.50 per share, about $1.46 billion in equity value. The offer follows a merger agreement signed October 8, and Pacira’s board unanimously recommends that shareholders tender. It expires at the end of November 16 unless extended. Closing requires a majority of shares to be tendered and antitrust clearance; there is no financing condition. A second-step merger under Delaware Section 251(h) will follow without a shareholder vote. The deal adds Pacira’s non-opioid pain franchise, led by EXPAREL, to Viatris’ branded portfolio. (Link)
Spenser Lin No Comments

Meet with our Team at the Opus Connect NYC Healthcare Conference (November 4–5, 2026 | New York, NY)

Lawrence, Evans & Co., LLC is attending the Opus Connect NYC Healthcare Conference, a two-day event bringing together capital providers and investment bankers focused exclusively on healthcare deals.

Hosted at Greenberg Traurig, the conference features thought-leadership panels on Day 1 and structured 1:1 Deal Connect meetings on Day 2—designed for efficient, high-quality conversations with relevant counterparties.

We advise lower middle-market healthcare companies on mergers & acquisitions, capital raising, and special situations. Our work is concentrated with providers, business services, and software companies typically up to $250M in revenue and/or $15M in EBITDA.

Core sectors we cover include:
Behavioral Health & Mental Health • HCIT & Digital Health • Longevity • RCM • Physician Groups • Home Health, Hospice & Senior Housing • Pharma Services • Cyber & Managed IT • Supply Chain • Space Health & Life Science • Innovation

If you’re attending and would like to connect, reach out or stop by to meet the team.

Event details:
https://www.opusconnect.com/events/nyc-healthcare-conference-nov-4th-and-5th-2026/

#Healthcare #MiddleMarket #InvestmentBanking #HCIT #BehavioralHealth #Longevity #DigitalHealth #ACG #OpusConnect

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update October 26th, 2026

Healthcare News and Deals

  1. EQT Private Equity has agreed to acquire QIAGEN N.V. (NYSE: QGEN) in a recommended all-cash voluntary public takeover offer valuing the molecular testing company at approximately $12.1 billion enterprise value. EQT XI, through Crown NL Bidco, is offering €46.50 per share in cash — a 40.3% premium to the unaffected XETRA close on July 8. Including about $1.1 billion of net debt, the deal values QIAGEN at roughly $12.1 billion. The Dutch tools and diagnostics company has been the subject of takeover talk for years. Both boards are recommending the offer after a strategic review. Affiliates of the Abu Dhabi Investment Authority and Canada Pension Plan Investment Board are co-investing. QIAGEN will keep its name and brand. (Link)
  2. HealthSpan Partners to Acquire Surgery Partners, Establishing a Leading Outpatient Surgical Care Platform HealthSpan Partners has agreed to buy Surgery Partners (NASDAQ: SGRY), the Bain Capital-backed operator of ambulatory surgery centers and surgical hospitals. Reports put the value at about $6 billion, including roughly $3.5 billion of debt, with Bain keeping its nearly 40% stake. Surgery Partners runs more than 170 surgical facilities across 30 states. HealthSpan is an affiliate of Bon Secours Mercy Health and is picking up a large outpatient surgical footprint. (Link)
  3. AEA Investors-Backed American Oncology Network Agrees to a $2.4 Billion Sale to Cencora, Adding 350+ Community Oncology Providers to Cencora’s Physician MSO Platform. Cencora (NYSE: COR) signed a definitive agreement on October 20 to buy the roughly 96% of Fort Myers-based American Oncology Network (OTCQX: AONC) it does not already own. The deal values AON at $2.4 billion enterprise value — $2.3 billion at closing plus up to $100 million in contingent value rights. Some AON holders can roll up to 25% of their equity; if they do, Cencora expects to write a check of about $1.7 billion for 75% ownership. AON brings more than 350 providers across 21 states and adds 12 new states to Cencora’s MSO footprint. Clinical decisions stay with AON physicians. It is Cencora’s fourth physician-platform deal since January 2025, after Retina Consultants of America, OneOncology and the EyeSouth retina business. (Link)
  4. Kohlberg Is Buying Alcanza Clinical Research from Martis Capital for Approximately $800–850 Million Axios Pro reported that Kohlberg is buying Alcanza Clinical Research from Martis Capital for between $800 million and $850 million. Alcanza is a clinical research site network founded in 2021 that focuses on inclusive trial access and runs more than 25 sites across the U.S. and Puerto Rico. It does Phase I–IV studies for pharma sponsors and CROs. (Link)
  5. Blackstone- and TPG-Backed Hologic Signs a Definitive Agreement to Acquire Reveal Genomics, Maker of the HER2DX Breast Cancer Test Hologic, now owned by Blackstone and TPG after a take-private of up to about $18.3 billion, has agreed to buy Barcelona-based Reveal Genomics. Reveal makes the HER2DX genomic test, which helps guide therapy for HER2-positive breast cancer. The test sits alongside Hologic’s Breast Cancer Index assay and adds another treatment-selection tool. It is the first clear sign that the new owners plan to use Hologic as a buy-and-build platform in women’s-health diagnostics. (Link)
  6. Apogem Capital Leads a Minority Investment in Revelstoke-Backed Family Care Center, Returning Capital to LPs While Revelstoke Stays In Family Care Center, the outpatient mental health platform backed by Revelstoke Capital Partners, closed a minority equity sale led by Apogem Capital. Revelstoke is staying in. Since Revelstoke partnered with founder Dr. Chuck Weber in December 2020, the company has grown entirely by opening new clinics — from four locations in one state to more than 50 across five states. It now has more than 800 providers and expects nearly 1 million treatment sessions in 2026, across therapy, psychiatry, TMS and intensive outpatient programs. Revelstoke described the deal as a way to return capital to its LPs without selling the whole company. Jefferies advised Family Care Center. (Link)
  7. EQT-Backed Sagility Agrees to Acquire Tennessee’s Chirok Health for Up to $32.35 Million, Adding Clinical Documentation Integrity and Coding Capability Sagility (US) Holdings, a subsidiary of the EQT-backed healthcare BPO Sagility, signed a definitive agreement on October 21 to buy Chirok Health, a Tennessee firm that does revenue cycle management, clinical documentation integrity and medical coding. The price is $20 million at closing plus up to $12.35 million in earnout. Chirok did about $9 million of revenue in 2025. The deal adds provider-side capability for Sagility. (Link)
  8. Altaris-Backed Tegria Acquires CloudWave, Its First Add-On Since the Providence Carve-Out, to Build a Healthcare Cybersecurity and Hosting Platform Tegria, the healthcare consulting, managed services and technology company that Altaris carved out of Providence in January 2026, bought CloudWave. CloudWave does cloud hosting, managed IT and cybersecurity (LECO sold BlueOrange to Cloudwave in 2025) only for healthcare clients, and it runs a dedicated 24/7 security operations center. CloudWave CEO Erik Littlejohn becomes president of Tegria’s Enterprise Technical Solutions. It is Tegria’s first add-on since the carve-out. (Link)
  9. Renovus Capital Partners Strikes a Deal for Chicagoland Orthopedic Home Health Provider Aspire Home Health Care Renovus Capital Partners, the Philadelphia-area lower-middle-market firm that already owns Louisiana home health and hospice platform Superior Health Holdings, has agreed to buy Aspire Home Health Care. Aspire was founded in 2013 and is based in Morton Grove, Illinois. It provides skilled nursing and therapy at home for patients recovering from orthopedic procedures, surgeries and complex conditions. The deal gives Renovus a post-surgical home health business in the Chicago market. (Link)
  10. Kohlberg-Backed Trinity Life Sciences Acquires Verix to Add AI-Driven Commercial Execution Tools for Pharma Trinity, the life sciences commercialization advisory and analytics firm that Kohlberg & Company has owned since 2021, bought Verix. Verix’s Tovana platform uses AI to give pharmacommercial teams next-best-action recommendations, patient finding and HCP targeting, and it is used by large pharma companies. The deal moves Trinity from strategy and insights into software that field teams actually use day to day. (Link)
  11. New Harbor Capital’s LGM Pharma Acquires New Jersey Contract Lab Sannova Analytical LGM Pharma, the API sourcing and CDMO platform that New Harbor Capital has majority-owned since 2017, bought Sannova Analytical. Sannova is a Somerset, New Jersey contract lab that does bioanalytical and CMC testing for pharma and biotech companies. It had been backed by SFW Capital Partners since 2022. The deal adds an East Coast testing operation to LGM’s development and manufacturing services. (Link)
  12. Blue Sea Capital-Backed One Physics Adds Two West Coast Medical Physics Firms, Expanding into the Pacific Northwest and Northern California One Physics, the largest outsourced medical physics company in North America, is buying two firms that do diagnostic medical physics and radiation safety work in the Pacific Northwest and Northern California. Blue Sea Capital has backed One Physics since 2019 and moved it into a single-asset continuation vehicle earlier this year. The company has already done 22 acquisitions and serves more than 7,000 client sites in 45+ states with over 210 physicists. (Link)
  13. HCAP Partners- and Salt Creek-Backed Real Diagnostics Adds Saliva-Based Oral Health Testing Firm SimplyTest Real Diagnostics (RealDx), the Maryland-based high-complexity molecular lab that Salt Creek Capital and HCAP Partners bought in September 2025, acquired SimplyTest. SimplyTest makes saliva-based tests, including its PERIO test, that identify bacteria linked to gum disease, and it sells to dentists and functional medicine practices. The add-on gives RealDx, which serves physician offices and clinics in 17 states, a cash-pay dental product line next to its reimbursed UTI, STI and respiratory testing. (Link)
  14. Thompson Street Capital-Backed Savillex Completes Carve-Out of Entegris’ Life Sciences Fluid Management Business Savillex, the Eden Prairie, Minnesota high-purity fluoropolymer and single-use bioprocessing company backed by Thompson Street Capital Partners, completed its acquisition of Entegris’ (Nasdaq: ENTG) life sciences fluid management business. The business includes Aramus and PE bioprocess bags, single-use assemblies and components. The carve-out deepens Savillex’s position with biopharma and cell and gene therapy manufacturers, and lets Entegris focus on semiconductor materials. It follows Savillex’s 2024 acquisition of Optimum Processing. Sidley advised Savillex. (Link)
  15. Sopris Capital Merges the Blackford Analysis Imaging-AI Platform, Carved Out of Bayer, into Portfolio Company Azra AI Azra AI said on October 20 that it had completed the acquisition of Blackford Analysis from Sopris Capital. Sopris had carved Blackford out of Bayer earlier in the month. Blackford’s vendor-neutral orchestration platform gives radiology departments access to more than 130 imaging-AI applications from 45+ vendors. Azra identifies patients with cancer and other complex conditions and coordinates their follow-up care. Putting the two together connects the imaging finding to the care pathway that follows it. (Link)
  16. Pacific Lake Partners-Backed Vitana Pediatric & Orthodontic Partners Acquires Louisiana’s Hollis Orthodontics, Its Fifth Deal of 2026 Vitana Pediatric & Orthodontic Partners, a dentist-led partnership organization backed by Pacific Lake Partners that focuses only on pediatric dental and orthodontic practices, bought Hollis Orthodontics in Prairieville, Louisiana, outside Baton Rouge. The practice is led by Dr. Bryan Hollis. Vitana now supports practices in Florida, Alabama, Louisiana, Pennsylvania and New Jersey. This is its fifth deal of 2026. (Link)
  17. DuneGlass Capital-Launched Aviva Aesthetics Enters Florida Through a Partnership with Allenby Cosmetic Dermatology Aviva Aesthetics, the founder-led medical aesthetics network that DuneGlass Capital launched, partnered with Allenby Cosmetic Dermatology, the practice of cosmetic dermatologist Dr. Janet Allenby. It is Aviva’s first Florida location, about seven weeks after the Perfect Skin Center partnership took the platform to 20 sites. Aviva markets its “Entrepreneur Equity” model to founders who have turned down traditional private equity MSO structures: founders keep decision-making authority and financial upside. (Link)
  18. Redesign Health and Sheba Medical Center’s ARC Global Merge in an Approximately $2 Billion Combination to Build an End-to-End Health System Innovation Platform Redesign Health, the venture and applied technology firm that has launched more than 60 healthcare companies, is merging with ARC Global, the innovation arm of Israel’s Sheba Medical Center. The combined company is valued at about $2 billion, according to a source familiar with the deal. The parties have also agreed to buy AVIA, the health-system digital technology advisory firm. Brett Shaheen will be CEO; Stephen Klasko, M.D., will chair the board; and ARC founder Eyal Zimlichman, M.D., will become vice chair. The idea is to put engineering, AI and capital inside health systems so clinician-originated ideas can become products and companies that scale across a network of more than 100 systems. (Link)
  19. Horizon Mutual Holdings, parent of Horizon Blue Cross Blue Shield of New Jersey, has entered an agreement to acquire Summit Health New Jersey, including its New Jersey CityMD urgent care centers, in a transaction reported at more than $1 billion. Horizon confirmed the agreement, which is subject to regulatory review and could close by year-end. Summit Health is one of New Jersey’s largest multispecialty physician networks; the New Jersey portion includes primary, specialty and 39 CityMD urgent care sites. It is Horizon’s largest deal since its 2022 conversion to a nonprofit mutual holding company. Horizon said the acquisition is meant to preserve access, improve quality and affordability for members, and support continued independence of Summit’s physicians. (Link)
  20. Alcon Acquires Rhode Island’s Neurotech Pharmaceuticals for $550 Million Plus Milestones, Picking Up ENCELTO, the Only FDA-Approved MacTel Type 2 Therapy Alcon completed the acquisition of Neurotech Pharmaceuticals on October 20 for $550 million upfront, plus possible contingent payments tied to commercial milestones. The deal brings in ENCELTO (revakinagene taroretcel-lwey), an encapsulated cell therapy implant approved in March 2025 and the only FDA-approved treatment for macular telangiectasia type 2. Neurotech estimates there are about 25,000 MacTel patients in the U.S., with 2,000 to 3,000 new diagnoses each year. Alcon expects the deal to modestly add to sales growth and slightly reduce core EPS in 2027, then add to EPS after that. (Link)
  21. Labcorp Agrees to Buy Myriad Genetics’ Prenatal Health Testing Business for $210 Million in Cash as Myriad Narrows Its Focus to Oncology Labcorp (NYSE: LH) signed a definitive agreement to buy Myriad Genetics’ (NASDAQ: MYGN) Prenatal Health testing business, including the Prequel, Foresight, SneakPeek and FirstGene tests, for $210 million in cash plus inventory value at closing. Labcorp expects about $160 million of first-year revenue, slight accretion to adjusted EPS in year one, and average diagnostics-segment margins by the end of year two. The carve-out comes out of Myriad’s strategic review, after prenatal revenue fell about 16% in the first half of 2026. It follows closely on Labcorp’s $722 million BioReference deal. (Link)
  22. Risant Health has signed a definitive agreement to acquire INTEGRIS Health, Oklahoma’s largest nonprofit health system, pending regulatory approvals. INTEGRIS Health would become Risant’s third member system after Geisinger and Cone Health. Headquartered in Oklahoma City, INTEGRIS operates roughly 20 acute and specialty hospitals and the state’s largest physician network, employing about 13,000 people. It will keep its name, medical staff, brand and leadership. Risant, backed by Kaiser Permanente, is focused on value-based care; INTEGRIS leadership pointed to access to additional capital, technology including Epic, and clinical tools that the system could not scale on its own. (Link)
  23. Bolt Biotherapeutics, Inc. (NASD: BOLT) has completed the acquisition of Prana Therapies, Inc. in a stock-for-stock reverse merger concurrent with a $120 million private placement. The sign-and-close reverse merger exchanges Prana equity for Bolt common stock and Series D non-voting convertible preferred stock. A concurrent financing raises $120 million in upfront gross proceeds from the purchase of Series D preferred, with up to an additional $60 million available if accompanying warrants are exercised. Investors include Deep Track Capital, ADAR1 Capital, Andreessen Horowitz, LYFE Capital, Eventide Asset Management, Casdin Capital and Soleus Capital. The combination focuses on Prana’s INSPIRE platform and lead bispecific antibody PRA-216 (IL-4Rα/TSLP). Proceeds are expected to fund operations into 2028. Sheila Gujrathi, M.D., former Prana CEO, joins as chief strategy officer and board member. (Link)
  24. OpenAI Acquires a16z-, 8VC- and Insight-Backed Orchestra Bio to Bring Agentic Drug-Program Management into Its Rosalind Life Sciences Suite OpenAI acquired San Francisco-based Orchestra Bio on October 20. Orchestra’s AI agents help biopharma teams coordinate drug development programs — they monitor studies, track timelines and flag delays that can spread across a program. Orchestra came out of stealth in 2025 with about $20 million from investors including Andreessen Horowitz, 8VC and Insight Partners. Its team and technology will be folded into Rosalind, OpenAI’s life sciences offering, which already has pharma partners such as Moderna and Novo Nordisk. (Link)
  25. Hackensack Meridian Health Signs a Definitive Agreement to Acquire Hunterdon Health, Committing $230 Million to the Central New Jersey System Hackensack Meridian Health, New Jersey’s largest health system, signed a definitive agreement to acquire Hunterdon Health. Hunterdon is anchored by the 184-bed Hunterdon Medical Center teaching hospital and has more than 30 medical practices. HMH committed $230 million in investment, and the deal would bring it to 19 hospitals. No closing timeline was given. (Link)
  26. Beacon Biosignals Acquires Snap Diagnostics to Expand EEG-Enabled Home Sleep Testing Nationwide Beacon Biosignals, an AI-powered precision neurotechnology company, has acquired Snap Diagnostics, a national home sleep testing provider. Snap operates as a Medicare-registered Independent Diagnostic Testing Facility accredited by The Joint Commission and serves patients in all 50 states with end-to-end shipping, scoring and interpretation. The acquisition more than doubles Beacon’s patient reach and gives it a channel to bring its FDA-cleared EEG headband technology into primary care, telehealth and specialty settings starting in 2027. (Link)
  27. CentraCare and Stellis Health Announce Plans to Integrate, with Completion Targeted for January 1, 2027 CentraCare, the integrated nonprofit health system serving Central, Southwest and West Central Minnesota, and Stellis Health, a physician-owned medical group with more than 60 providers in Wright County, have announced plans for Stellis to become part of CentraCare. The combination builds on a longstanding partnership that already includes a shared Epic electronic medical record and collaboration at CentraCare – Monticello. Stellis shareholders have voted to proceed. (Link)
  28. Further Acquires Welbi to Combine Senior Living Sales AI with Resident Experience Management Further, the Charleston-based AI platform for senior living sales and marketing, has acquired Ottawa-based Welbi, a resident experience platform. Together they reach more than 8,000 senior living communities. Further’s suite (ProspectAI, SalesAI, ResidentAI, OpsAI) helps operators attract and convert prospects; Welbi helps communities personalize daily programming and track engagement. Welbi founder and CEO Elizabeth Audette-Bourdeau will continue to lead Welbi’s operations. (Link)
  29. Vimian Group Expands Its Veterinary Surgical Offering Through the Acquisition of Norfolk Medical Products Vimian Group AB (publ), the Stockholm-based animal health company, has signed an agreement to buy Norfolk Medical Products, a family-owned U.S. provider of implants and consumables for veterinary soft-tissue surgery. Norfolk, founded in 1981, does about $6.9 million in revenue and specializes in vascular access ports and related implantable solutions. The deal is Vimian’s first move into specialized soft-tissue surgery and is expected to have a marginal impact on 2026 earnings. (Link)

Venture Deals and Other

  1. Star Therapeutics has raised $200 million in private financing to advance its preclinical pipeline of novel biologics after prior exits of subsidiary assets. The round was co-led by OrbiMed and Janus Henderson Investors, with participation from RA Capital Management, Sofinnova Investments and others. Star, founded by Adam Rosenthal, has a history of discovering biologics and advancing them through subsidiaries that were later sold or taken public, including the sale of Vega Therapeutics to Incyte and the IPO of Electra Therapeutics. Rosenthal called the financing a reset, with the company focusing on early-stage programs rather than a hub-and-spoke model going forward. Proceeds will be used to move current preclinical assets into the clinic. (Link)
  2. OpenAI Startup Fund and Founders Fund Co-Lead a $45 Million Round for Coherence Neuro’s AI-Enabled Brain Tumor Implant The round was co-led by OrbiMed and Janus Henderson Investors, with participation from RA Capital Management, Sofinnova Investments and others. Star, founded by Adam Rosenthal, has a history of discovering biologics and advancing them through subsidiaries that were later sold or taken public, including the sale of Vega Therapeutics to Incyte and the IPO of Electra Therapeutics. Rosenthal called the financing a reset, with the company focusing on early-stage programs rather than a hub-and-spoke model going forward. Proceeds will be used to move current preclinical assets into the clinic. (Link)
  3. FirstMark Capital Leads a $40 Million Series A for Baba, with CVS Health Ventures Joining, to Build AI Care Teams for Medicare and Medicaid Members New York-based Baba, an applied AI company working on the Medicare and Medicaid experience, raised a $40 million Series A led by FirstMark Capital. CVS Health Ventures and Valtruis joined, and General Catalyst, Genius Ventures and Ground Up Ventures returned. The funding will expand Baba’s clinical care teams, advance its AI research and grow its health plan partnerships. (Link)
  4. Healthleap has raised $38 million in seed and Series A funding to expand its AI platform that flags at-risk hospital patients from electronic medical records. The total comprises an $8 million seed round co-led by Sequoia Capital and First Round Capital and a $30 million Series A led by Hummingbird Ventures. Founded in 2022 by siblings Jemima and Josiah Meyer, the South African-origin company analyzes clinical notes, labs, vitals and medication records to surface risk scores for conditions such as malnutrition and delirium. It is used in more than 50 hospitals including Penn Medicine, Cedars-Sinai, Houston Methodist and Emory Healthcare. (Link)
  5. Allumia Ventures Leads a $10 Million Series A for Home-Based Lung Disease Telehealth Provider Kivo Health Kivo Health, a telehealth provider of virtual pulmonary rehabilitation and care for COPD and other chronic lung diseases, raised a $10 million Series A led by Allumia Ventures, according to Axios Pro. Home-based respiratory care is an area health plans and risk-bearing providers have been looking at for value-based contracts. (Link)
  6. Zai Lab Limited (NASD: ZLAB; HKEX: 9688) has entered a securities purchase agreement for a $250 million PIPE financing of American Depositary Shares. Zai Lab agreed to sell 11,340,000 ADSs at $22.04 each, for expected gross proceeds of about $250 million before fees. The financing is led by TCGX and includes participation from abrdn World Healthcare Fund, ADAR1 Capital Management, Balyasny Asset Management, Cormorant Asset Management, Frazier Life Sciences, RA Capital Management, RTW Investments, Wellington Management and others. Net proceeds are intended primarily to support continued global development of zocilurtatug pelitecan (zoci), the company’s DLL3-targeting antibody-drug conjugate. Leerink Partners is the exclusive placement agent. (Link)

IPOs:

  1. Lycia Therapeutics Prices Upsized $317.5 Million Initial Public Offering at $18 per Share Lycia Therapeutics, Inc. (NASD: LYCA), a clinical-stage biotechnology company developing LYTAC degraders of disease-causing extracellular proteins, priced its upsized IPO of 17,640,000 shares at $18.00 per share, for expected gross proceeds of about $317.5 million. The company had originally marketed 14.7 million shares at $16–$18. Lead programs include LCA-0061 (an IgE degrader for food allergy) and LCA-0321 (an autoantibody degrader for Graves’ disease). Jefferies, TD Cowen, Evercore ISI and Guggenheim Securities are joint book-running managers. The platform is based on work by Nobel laureate Carolyn Bertozzi. (Link)
  2. Anthropic Files Public S-1 for Nasdaq IPO Under Ticker (NASD:ANT) Anthropic, the AI lab behind the Claude model family, has filed a public S-1 registration statement with the SEC for an initial public offering on Nasdaq under the ticker ANT. The Claude maker is targeting a valuation of $1.5–2 trillion, which would make it one of the largest IPOs on record and roughly double the $965 billion mark from its May funding round. First-half 2026 revenue was $16.3 billion, against about $4.6 billion for all of 2025. Third-quarter revenue reached $16.8 billion, up about 45% sequentially, and the company said it was profitable on an adjusted basis. The $80.7 billion first-half net loss is largely a non-cash charge tied to the rising valuation. (Link)
Spenser Lin No Comments

Q3 2026 Behavioral Health Industry M&A and Investment Update

Recently released Q3 2026 Behavioral Health Industry M&A and Investment Update:

SUD M&A volume has fallen from a record 𝟱𝟬 𝗱𝗲𝗮𝗹𝘀 𝗶𝗻 𝟮𝟬𝟮𝟭 to 𝟭𝟴 𝗶𝗻 𝟮𝟬𝟮𝟱. PitchBook data also showed MSO deal volume down about 𝟯𝟲% as 𝘀𝘁𝗮𝘁𝗲 𝗹𝗮𝘄𝘀 𝗿𝗲𝘀𝘁𝗿𝗶𝗰𝘁𝗶𝗻𝗴 𝗽𝗿𝗶𝘃𝗮𝘁𝗲-𝗲𝗾𝘂𝗶𝘁𝘆 𝗼𝘄𝗻𝗲𝗿𝘀𝗵𝗶𝗽 𝗶𝗻 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 take effect.

Behavioral health stocks fell an average of 𝟰.𝟯𝟵% in the quarter while the 𝗦&𝗣 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗜𝗻𝗱𝗲𝘅 rose about 𝟲%. LifeStance Health gained 𝟭𝟮.𝟯𝟮%  after beating and raising guidance; Acadia Healthcare slipped 𝟲.𝟴𝟳% and BrightSpring Health Services fell 𝟭𝟴.𝟲𝟯%.

Q3 2026 saw 𝗠𝗲𝗱𝗶𝗰𝗮𝗶𝗱 𝗽𝗮𝘆𝗺𝗲𝗻𝘁 𝗿𝘂𝗹𝗲𝘀 𝗿𝗲𝘄𝗿𝗶𝘁𝘁𝗲𝗻 and 𝗯𝗲𝗵𝗮𝘃𝗶𝗼𝗿𝗮𝗹 𝗵𝗲𝗮𝗹𝘁𝗵 𝗮𝘀𝘀𝗲𝘁𝘀 𝗿𝗲𝗽𝗿𝗶𝗰𝗲𝗱 as a result. Centers for Medicare & Medicaid Services (CMS) proposed limits on the provider taxes states use to fund their share Medicaid (estimated to reduce federal Medicaid spending by $𝟮𝟰𝟲 𝗯𝗶𝗹𝗹𝗶𝗼𝗻 over 2026–2035), while eligibility continued to contract ahead of the 𝗝𝗮𝗻𝘂𝗮𝗿𝘆 𝟭, 𝟮𝟬𝟮𝟳 work-requirement deadline. State-directed payment caps and 340B payment cuts added further pressure.

Distress defined several of the quarter’s larger provider transactions. Spero Health acquired CleanSlate Centers, keeping a provider with more than 65 centers from shutting down. BayMark Health Services announced completion of a restructuring that hands control to its lenders. A $610 million unrated municipal bond issue intended to finance Clearview Capital, L.P.’s sale of Advantage Behavioral Health failed to sell even at yields up to 𝟴.𝟮𝟱%.

See our August 2026 Special Report: The SUD Capital Reckoning.

Notable transactions and financings:
• UHS acquired Talkspace for $835M.
• Eli Lilly and Company completed its acquisition of AtaiBeckley (up to ~$3.8B including CVR).
• Sword acquired Headspace (closed October 1; price undisclosed).
• Spero Health acquired CleanSlate Centers (closed July 1; averted shutdown).
• HCA Healthcare sold Dominion Hospital to Hill Valley Healthcare for $25M.
• Cityblock Health raised $116M Series E led by General Catalyst.
• Allswell raised $6.76M seed led by Rethink Impact, LP.

===

#BehavioralHealth #MentalHealth #SubstanceUse #SUD #HealthcareMergers #HealthcareAcquisitions #PrivateEquity #InvestmentBanking #HealthTech #Medicaid #Talkspace #UniversalHealthServices #EliLilly #AtaiBeckley #SwordHealth #Headspace #CleanSlate #SperoHealth #BayMark #LifeStance #Acadia #BrightSpring #Cityblock #QuarterlyUpdate #LECO

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update October 19th, 2026

Healthcare Weekly News and Deals – Oct 19th, 2026

  1. Agilent Technologies (NYSE: A) has agreed to acquire digital-pathology software provider Proscia in an all-cash deal worth $240 million at closing plus up to $30 million in milestones Proscia’s enterprise software integrates slide scanners, laboratory information systems, and AI tools. The platform integrates slide scanners, laboratory information systems, image analysis, and AI tools into a single operating layer used by more than 4,000 labs, hospitals, and clinics, including 16 of the top 20 pharmaceutical companies. Trailing-twelve-month revenue exceeds $18 million. The companies have partnered since 2022. The acquisition advances Agilent’s strategy in the roughly $5 billion pathology market as laboratories continue to adopt digital workflows for clinical and research use. Digital adoption continues to expand across both diagnostic and research laboratories. (Link)
  2. Welsh, Carson, Anderson & Stowe is selling a $2.8 billion stake in the CenterWell senior primary-care joint venture to BlackRock’s (NYSE: BLK) HPS Investment Partners. $2.8 billion stake in the CenterWell senior primary-care joint venture to HPS Investment Partners, the private-credit arm of BlackRock (NYSE: BLK). The joint ventures operate nearly 150 clinics that provide value-based primary care for Medicare Advantage patients as part of Humana’s (NYSE: HUM) CenterWell business. The sale transfers a scaled senior-care platform to an institutional buyer and reflects continued capital interest in Medicare Advantage-aligned primary care models. Value-based senior primary care remains a focus for institutional capital. (Link)
  3. Blackstone (NYSE: BX) has agreed to sell ZO Skin Health to Galderma (SIX: GALD) for $1.5 billion. ZO Skin Health, founded by dermatologist Zein Obagi, generated approximately $330 million in net sales over the prior twelve months. 5 billion. The physician-dispensed brand, founded by dermatologist Zein Obagi, generated approximately $330 million in net sales over the prior twelve months and markets more than 40 products in more than 40 countries. The implied multiple is roughly 4.5x revenue. The transaction gives Galderma a scaled professional skincare brand within the medical-aesthetics category and provides Blackstone an exit. Physician-dispensed skincare continues to attract strategic buyers in medical aesthetics. (Link)
  4. Zocdoc has acquired fellow New York company Sohar Health, which automates insurance-eligibility verification, in its first-ever acquisition. Zocdoc’s appointment-booking platform connects patients to in-network providers across more than 10,000 insurance plans. Sohar automates insurance eligibility verification and in-network status checks. The combination adds automated verification directly into the booking workflow and builds on an existing partnership. Zocdoc has also integrated with Google’s Gemini and Yelp, expanding its role in healthcare-access infrastructure. Reducing verification friction supports higher conversion to completed appointments. The platform now covers verification as part of the end-to-end booking experience. (Link)
  5. Parkview Health, a 16-hospital Indiana nonprofit system, is acquiring nationwide shared-services vendor Ovation Healthcare to become its sole owner. Ovation Healthcare partners with more than 500 healthcare organizations across 48 states. Ovation offers leadership advisory, spend management, revenue cycle management, and technology services, primarily to independent and rural hospitals. Parkview will become the sole owner while Ovation continues to operate as a separate organization with its own governance. The deal extends Parkview’s operational capabilities to a national provider base. Shared-services platforms help independent hospitals achieve scale without full affiliation. Ovation’s client base spans critical-access hospitals to larger systems. (Link)
  6. Value-based-care accelerator Diverge Health is merging with Medical Home Network (MHN), a supporter of federally qualified health centers. Diverge accelerates value-based care for independent primary-care practices, while Medical Home Network supports federally qualified health centers. Medical Home Network will operate on the Diverge platform while both brands remain distinct. In 2027 the combination is expected to partner with nearly 100 FQHCs, more than 300 independent practices, and more than 20 Medicaid and Medicare partners across nine states, covering approximately 500,000 members and $3 billion in medical spending. The merger pairs independent-practice reach with specialized Medicaid and FQHC expertise. (Link)
  7. HealthpointCapital has made a significant investment in Ospitek, a provider of surgical operations and patient-flow intelligence software. Ospitek’s AI- and IoT-powered platform delivers real-time visibility across the surgical episode of care, helping hospitals and ambulatory surgery centers improve operating-room throughput and team coordination. The capital supports technology development and commercial expansion. The investment aligns with HealthpointCapital’s exclusive focus on musculoskeletal healthcare and tools that address operational inefficiencies in orthopedic and surgical settings. Operating-room efficiency tools are increasingly relevant for both hospitals and ambulatory centers. Throughput and room utilization remain key economic drivers in surgical facilities. (Link)
  8. VeloSource, backed by Interlock Equity, has landed a strategic investment from UPMC Enterprises. VeloSource, backed by Interlock Equity, has received a strategic investment from UPMC Enterprises. VeloSource is a locum tenens physician-staffing agency that operates on the Syncx workforce-technology platform. The investment from UPMC’s venture arm adds a health-system strategic partner to the ownership group. Persistent physician shortages continue to support demand for technology-enabled locum staffing. The combination of private equity and health-system insight supports further scaling of the platform. Health-system venture participation adds distribution insight alongside private equity ownership. Locum platforms that combine technology with clinical relationships continue to attract capital. (Link)
  9. Carenet Health has acquired conversational-AI patient-engagement company Orbita in its 11th acquisition. Orbita provides a conversational and agentic AI platform for patient engagement, digital front door, and care navigation, with integrations to major EHR and CRM systems. Founded in 2015, the platform has delivered more than 50 million automated interactions for over 1.5 million patients. Health systems have reported reductions in same-day cancellations and gains in patient throughput. The acquisition embeds clinical-grade agentic AI into Carenet’s technology stack. Embedding agentic AI is intended to reduce manual steps while maintaining clinical oversight. (Link)
  10. Carenet Health has acquired healthcare AI and data-engineering consultancy Invene, its 12th acquisition. Invene is a healthcare-focused AI and data-engineering consultancy founded in 2018 by James Griffin. The firm has worked with 20 Fortune 100 companies, helped launch more than 400 products reaching over one billion users, and appeared on the Inc. 5000 list. Invene will operate as a Carenet company. The addition expands Carenet’s AI strategy, data engineering, and interoperability capabilities alongside its existing engagement services. Consecutive AI acquisitions reinforce Carenet’s integrated technology and services approach. (Link)
  11. Fengate Private Equity has taken a majority stake in Florida clinical-research network Clinical Research of West Florida (CRWF). Clinical Research of West Florida operates three research facilities across Tampa and Clearwater, including a Phase I unit. CRWF operates three research facilities across Tampa and Clearwater, including a dedicated Phase I unit. The investment gives Fengate exposure to the clinical-trial site-management segment, where sponsors are consolidating trials with scaled, multi-therapeutic operators. Institutional backing is expected to support capacity expansion, additional sites, and patient-recruitment capabilities valued by pharmaceutical sponsors. Sponsors value multi-site networks for recruitment speed and operational consistency. (Link)
  12. LUX Infusion, backed by Frazier Healthcare Partners, has acquired Suite Health, entering the Colorado specialty-infusion market. Suite Health provides specialty infusion therapy for patients receiving complex and recurring treatments. The bolt-on extends LUX’s geographic footprint and fits the playbook of building regional density in site-of-care infusion. The segment continues to benefit from the shift of complex drug administration out of hospitals into lower-cost ambulatory and home settings. Ambulatory infusion continues to attract investment as a lower-cost alternative to hospital administration. (Link)
  13. Alaunos Therapeutics (NASD: TCRT) has acquired Velaris Therapeutics in an all-stock deal alongside an oversubscribed $350 million private placement led by Fairmount, with Venrock Healthcare Capital Partners, T. Rowe Price, Wellington Management, Janus Henderson Investors, Access Biotechnology, BB Biotech, Perceptive Advisors, Sirenia Capital Management and ADAR1 Capital Management. Velaris develops therapies for pulmonary arterial hypertension. Concurrently, Alaunos completed an oversubscribed private placement of Series C non-voting convertible preferred stock led by Fairmount, with participation from Venrock Healthcare Capital Partners, T. Rowe Price, Wellington, Janus Henderson, and others. The placement raised roughly $350 million in gross proceeds to fund operations into 2029 for proof-of-concept data on VLR199 and VLR360. The combination of the acquisition and financing positions Alaunos for extended clinical runway. (Link)
  14. Gilead Sciences (NASD: GILD) has licensed three solid-tumor T-cell engagers from Vir Biotechnology (NASD: VIR) in a deal worth up to $1.9 billion. Gilead is paying $90 million upfront, consisting of $65 million in cash and $25 million in equity at a 30% premium, plus tiered royalties on future sales. The assets are dual-masked T-cell engagers designed for solid tumors. The transaction expands Gilead’s oncology pipeline with early-stage assets and provides Vir with non-dilutive capital and a strategic development partner. Dual-masked engagers are designed to improve therapeutic index in solid-tumor settings. (Link)
  15. AstraZeneca (NASD: AZN) and insitro have signed an AI drug-target-discovery collaboration worth up to roughly $1.5 billion. AstraZeneca (Nasdaq: AZN) and insitro have signed an AI drug-target-discovery collaboration. AstraZeneca is paying $40 million upfront, with up to roughly $1.46 billion in potential milestones across metabolic dysfunction-associated steatohepatitis and cardiomyopathies. Insitro will use its machine-learning platform to identify novel drug targets. The deal gives AstraZeneca access to AI-enabled discovery in two high-interest disease areas and provides insitro with upfront capital plus a path to development milestones. AI-enabled target discovery is increasingly used by large pharma to expand early pipelines. (Link)
  16. First Tracks Biotherapeutics (NASD: TRAX) has raised about $200 million in a private placement from Vestal Point Capital, TCGX, Sirenia Capital Management, First Light Asset Management, Affinity Asset Advisors and Trails Edge Capital Partners. The clinical-stage biotech agreed to sell 6,106,870 shares at $32.75 per share to institutional investors, including mutual funds. Proceeds are expected to support clinical development of the company’s pipeline. The financing provides capital for ongoing programs and reflects institutional demand for clinical-stage biotech assets with near-term data catalysts. Institutional participation signals confidence in the company’s clinical-stage assets. Near-term catalysts support the valuation. The placement adds runway. (Link)
  17. Recursion Pharmaceuticals (NASD: RXRX) has priced a $200 million stock offering, with participation from Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest and Driehaus Capital Management. Recursion Pharmaceuticals (Nasdaq: RXRX) has priced a $200 million underwritten offering of 61,540,000 Class A shares at $3.25 each. Participation includes Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest, and Driehaus Capital Management. The offering was oversubscribed. Proceeds will support the company’s AI-driven drug-discovery platform and clinical programs, adding balance-sheet capacity amid ongoing clinical data updates and a Sanofi partnership milestone. The follow-on strengthens the balance sheet for continued platform and clinical investment. Clinical data updates continue in parallel. Balance-sheet capacity increases. (Link)
  18. Janus Living (NYSE: JAN) has acquired the Harmony at Greensboro senior-living community for $123.5 million. The property includes independent living, assisted living, and memory care and marks Janus’s entry into North Carolina. The seller is an affiliate of Smith/Packett, which will continue to operate the community. Janus, which completed its IPO in March 2026, owns and operates its portfolio under RIDEA structures and focuses exclusively on senior housing. The acquisition expands the company’s footprint beyond its core Florida and Texas markets. (Link)
  19. TriGemX Bio and TCGX Acquisition Corp. (NASD: TCGX) have signed a definitive business combination for elismetrep. TriGemX Bio, developing elismetrep (an oral TRPM8 channel blocker for acute migraine now in Phase 3), and TCGX Acquisition Corp. (Nasdaq: TCGX) have signed a definitive business combination agreement. The combined company will trade as TriGemX Bio, Inc. under the ticker TGEM. The deal includes a $160 million PIPE at $10 per share from investors including Viking Global Investors and BVF Partners, plus approximately $86 million from the SPAC trust, for expected gross proceeds of $246 million and a post-transaction equity value of roughly $600 million. Proceeds will fund ongoing Phase 3 trials and commercial readiness. (Link)
  20. Healthspan Partners has agreed to acquire Centric Health for approximately €350 million. Healthspan Partners, a U.S. affiliate of Bon Secours Mercy Health, has agreed to acquire Centric Health, Ireland’s largest primary-care network. Centric operates 90 clinics with 420 GPs serving more than 700,000 patients and also has practices in the Netherlands and Germany. Founder and CEO Dr. Maurice Cox will retain a minority stake and continue to lead the business, with practices remaining independent under the Centric brand. The transaction, valued at approximately €350 million, is subject to Competition and Consumer Protection Commission approval. Bon Secours already operates hospitals in Ireland. (Link)
  21. Rush University System for Health and Endeavor Health have announced plans to merge. Rush University System for Health and Endeavor Health have announced their intention to combine into a single integrated academic health system. The merged organization would operate 12 hospitals and more than 400 care sites, employ more than 46,000 people, and serve more than 2 million patients annually across Northern Illinois and Northwest Indiana, with combined revenue approaching $11 billion. Endeavor has committed $1 billion over several years for community impact, academics and research, and care quality. J.P. Gallagher of Endeavor would lead the combined system. Close is targeted for early 2027, subject to regulatory review. (Link)
  22. Diazyme Laboratories has acquired the assets of Alfa Wassermann Diagnostic Technologies. Alfa Wassermann, founded in 1960 and based in West Caldwell, New Jersey, is an FDA-registered manufacturer of chemistry systems and reagents used in physician offices, hospitals, veterinary practices, and biopharma. The assets will be integrated into Diazyme’s operations. Diazyme, founded in 2000 and based in Poway, California, develops clinical diagnostic reagents for automated chemistry and immunoassay analyzers and is cGMP and ISO 13485 certified. Peter Napoli will continue to manage the Alfa Wassermann business within Diazyme. (Link)
  23. Vivos Therapeutics (NASD: VVOS) has agreed to acquire an 11% stake in SOD Sciences and a 50% interest in its proprietary test. Vivos Therapeutics (Nasdaq: VVOS) has entered into a definitive agreement to acquire an 11% fully diluted equity interest in SOD Sciences and a 50% undivided co-ownership interest in SOD’s proprietary pseudohypoxia early-warning test. Consideration is 12,000 shares of newly created Series C Convertible Preferred Stock with a stated value of $12 million; no cash is involved. The structure is intended to increase reported stockholders’ equity and support Nasdaq compliance while creating potential collaboration opportunities. The minority stake and stock-for-stock consideration keep the transaction small relative to other disclosed deals. (Link)
  24. Horizon Space Acquisition I Corp. has signed a definitive business combination with ArcheNova Biotech. Horizon Space Acquisition I Corp. has signed a definitive business combination agreement with ArcheNova Biotech, a clinical-stage company focused on MSC-derived extracellular vesicles and exosomes. The SPAC, which trades on the OTCQB, and ArcheNova will combine through a series of mergers. No transaction value or PIPE size was disclosed. ArcheNova’s lead program is a topical psoriasis candidate that has completed Phase I. The combination is expected to close in the first quarter of 2027, subject to approvals. The absence of a disclosed valuation places the deal lower in priority relative to sized SPAC transactions. (Link)

Venture Deals and Other

  1. Sunbound has raised a $24 million Series A led by TTV Capital — with Bling Capital, Fika Ventures, Live Oak Bank (NYSE: LOB) and the Ziegler Linkage Fund — and acquired Ohio-based Richter Healthcare Consultants to scale its senior-living revenue operating system. The round lifts total funding to $36 million and supports growth of its AI-powered revenue-cycle platform for senior-living and post-acute operators. Concurrently, Sunbound acquired Richter Healthcare Consultants, adding more than 25 years of skilled-nursing billing and Medicaid-eligibility expertise. Combined annualized payment volume is on track for $3 billion. The combination of software and domain expertise supports claims processing for senior-living operators. (Link)
  2. Suki has raised $90 million in Series E financing from new investors Healthier Capital, Crosslink Capital and Hercules Capital (NYSE: HTGC), with existing backers Venrock, Flare Capital Partners, Hedosophia, Philips Ventures and Zoom Ventures. The ambient clinical intelligence company will use the capital to expand beyond documentation into clinical reasoning, revenue cycle, and operational workflows. Suki serves more than 450 healthcare organizations and 30-plus technology partners. Patient encounters grew more than 190% year over year in 2026. Ambient AI adoption is expanding from documentation into broader clinical and operational workflows. (Link)
  3. Transformation Capital has led an $82 million Series C in Abby Care, joined by new investors CVS Health Ventures (CVS Health, NYSE: CVS), Frist Cressey Ventures and Pivotal Ventures and existing backers Khosla Ventures, Thrive Capital and Sequoia Capital. Transformation Capital has led an $82 million Series C in Abby Care, joined by new investors CVS Health Ventures, Frist Cressey Ventures, and Pivotal Ventures, and existing backers Khosla Ventures, Thrive Capital, and Sequoia Capital. Abby Care is an AI-powered care-at-home platform that trains and certifies family members as paid caregivers. Funds support market expansion, AI development, clinical research, and health-plan partnerships. Since its Series B in 2024, patient census has grown more than fivefold; the company now serves families across eight states. (Link)
  4. Sirona Medical has raised $40 million in Series D financing led by Avidity Partners, with participation from 8VC, GreatPoint Ventures and KLT Holdings. The cloud-native radiology software company will use the capital to reach cash-flow positivity and expand its platform. Sirona’s software is designed to modernize radiology workflows. The round supports continued product development and commercial growth in the radiology software market. Radiology software modernization remains a focus as imaging volumes and workflow complexity increase. Workflow tools remain relevant as imaging demand grows. (Link)
  5. Allara has raised $30 million led by Index Ventures and GV (Google Ventures), with new investors Camino Partners, Foreground and Family Fund. The virtual women’s-health provider, founded in 2020, lifts total funding to $75 million. Capital will accelerate enterprise partnerships and expand access to specialized care for conditions including PCOS and endometriosis. The financing supports growth of the virtual care model for women’s hormonal and reproductive health. Virtual women’s-health platforms continue to attract capital for specialized hormonal and reproductive care. (Link)
  6. Brellium has raised $23 million co-led by Left Lane Capital and First Round Capital, with Digital Health Venture Partners and prior backer Menlo Ventures, to expand its AI clinical-compliance platform. The company provides an AI clinical-compliance platform serving mental-health, autism, and post-acute providers, including Gentiva and Maxim Healthcare. Funds will expand the platform’s auditing and compliance capabilities. The raise supports scaling of AI-driven compliance tools for behavioral and post-acute providers. AI-driven compliance tools address documentation and audit requirements for behavioral and post-acute providers. Compliance automation is a focus for behavioral health operators. (Link)
  7. Hidden Variable has led an $18 million Series A in Sharp Performance, joined by Andreessen Horowitz, Commonweal Ventures, Wolfson Group, FJ Labs and the Ford Foundation. Hidden Variable has led an $18 million Series A in Sharp Performance, joined by Andreessen Horowitz, Commonweal Ventures, Wolfson Group, FJ Labs, and the Ford Foundation. Sharp Performance provides confidential performance coaching to first responders, including police officers, firefighters, and paramedics. Capital supports expansion of the coaching platform. The investment addresses mental-health and performance support for frontline emergency personnel. Performance and mental-health support for first responders is an emerging focus for specialized platforms. Specialized coaching platforms are gaining attention in emergency services. (Link)
  8. Ashvin AI has raised $16.5 million led by co-founder Mathew Mammen to automate durable medical equipment operations end to end. $16.5 million led by co-founder Mathew Mammen. The company automates durable medical equipment operations end to end, from referral to qualified order and prior authorization. Capital will expand prior-authorization capabilities and commercial reach in the DME market. The platform targets administrative inefficiencies in durable medical equipment workflows for providers and suppliers. Automating referral-to-authorization workflows reduces administrative burden in the DME supply chain.platform clears most orders without manual touch, addressing rising DME demand amid falling reimbursement and staffing shortages. (Link)
  9. Confido Health has raised a $12.5 million Series A extension led by Z47, taking its total Series A to $22.5 million, to automate healthcare administration with AI. $12.5 million Series A extension led by Z47, taking total Series A funding to $22.5 million. The company is expanding beyond AI-powered patient calls to automate connected administrative tasks across providers’ existing software systems. Capital supports product development and scaling of its CareOS platform. The extension funds broader automation of healthcare administrative workflows. CareOS expands automation beyond calls into connected administrative tasks across existing provider systems. Administrative automation continues to expand across provider workflows. The extension supports broader automation of administrative tasks. (Link)
  10. Threshold (Threshold Ventures) has led a $12 million Series A in Probably Genetic, with participation from Y Combinator and existing investors. Threshold Ventures has led a $12 million Series A in Probably Genetic, with participation from Y Combinator and existing investors. The AI platform for rare-disease research, diagnosis, and treatment brings total funding to $14 million. Capital will grow the core business and expand the dataset supporting drug discovery. The raise advances AI tools for rare-disease identification and research partnerships. Rare-disease datasets support both diagnostic identification and research partnerships with drug developers. AI tools for rare disease are attracting both clinical and research interest. (Link)
  11. Define Ventures has led an $11 million Series A in Readily, with participation from Y Combinator and the California Health Care Foundation Innovation Fund.Define Ventures has led an $11 million Series A in Readily, with participation from Y Combinator and the California Health Care Foundation Innovation Fund. Readily’s AI regulatory-compliance platform serves health plans and healthcare organizations, connecting regulatory requirements with policies, assigned actions, and audit trails. Capital supports product expansion and commercial growth. The platform addresses compliance complexity for payers and providers. Connecting regulations to actionable policies and audit trails addresses a persistent compliance gap for payers. Regulatory complexity continues to drive demand for compliance software. (Link)
  12. Fika Ventures and Evidenced have co-led an $8 million seed round in Otter Health, the new venture from healthcare operator Keith Florance. Fika Ventures and Evidenced have co-led an $8 million seed round in Otter Health. Otter Health helps health plans and providers manage care and costs through continuous, real-time clinical review and payer-provider collaboration. The company launched to address prior-authorization and utilization-management friction. Capital supports product development and initial commercial deployment of the prior-authorization platform. Real-time clinical review aims to reduce prior-authorization friction between plans and providers. Prior-authorization platforms address a persistent operational friction point. The platform targets utilization-management friction between plans and providers. (Link)
  13. Rethink Impact has led a $7 million seed round in Allswell, with Magnify Ventures, Ulu Ventures, Hopelab Ventures and existing investors Techstars and Amboy Street Ventures. Rethink Impact has led a $7 million seed round in Allswell, with Magnify Ventures, Ulu Ventures, Hopelab Ventures, and existing investors Techstars and Amboy Street Ventures. Allswell is a behavioral-health company built for the LGBTQ+ community, offering one-on-one virtual therapy, group programs, and trauma-informed care. Capital supports expansion of virtual behavioral-health services. The raise funds growth of specialized mental-health access. Specialized virtual therapy for LGBTQ+ populations addresses access gaps in behavioral health. Virtual behavioral health for underserved populations continues to attract seed capital. (Link)
  14. Redesign Health has led a $3.75 million round in Treso, with participation from Locke Health and KCRise Fund. Redesign Health has led a $3.75 million round in Treso, with participation from Locke Health and KCRise Fund. Treso is building a financial-management operating system for healthcare providers, combining accounting, receivables, expenses, and operational finance in one platform. Capital supports product development. The financing advances integrated financial tools for multi-site healthcare organizations. Integrated financial operating systems target multi-site providers seeking unified accounting and receivables tools. Provider finance tools are consolidating accounting and receivables functions. Multi-site providers are seeking unified financial management tools. (Link)
  15. AIN Ventures has led a $3.4 million pre-seed in TechNovaTime, with Speedinvest, Multiball Capital, Negative Burn Ventures and the Techstars Follow-On Fund.AIN Ventures has led a $3.4 million pre-seed in TechNovaTime, with Speedinvest, Multiball Capital, Negative Burn Ventures, and the Techstars Follow-On Fund. TechNovaTime builds AI-powered process intelligence and digital-workforce automation to streamline administrative workflows in healthcare. Capital supports early product development and initial customer deployments. The round funds automation tools for healthcare operations. Process intelligence and digital-workforce tools aim to reduce administrative load in healthcare operations. Digital workforce automation targets repetitive administrative tasks in healthcare. Administrative automation remains a focus for healthcare operations teams. (Link)
  16. Council Capital and the Anthemis Female Innovators Lab Fund have co-led a $3.2 million pre-seed in Collective X Health, with SoGal Ventures, Emerson Collective, Muse Capital and Segal Ventures. Council Capital and the Anthemis Female Innovators Lab Fund have co-led a $3.2 million pre-seed in Collective X Health, with SoGal Ventures, Emerson Collective, Muse Capital, and Segal Ventures. Collective X Health is a B2B women’s-health intelligence platform, co-founded by Dr. Stacy Sims, offering wearables, digital-health tools, and performance data for women’s health. Capital supports platform launch and early commercial efforts. Women’s-health intelligence platforms combining wearables and data are attracting early-stage capital. Early-stage capital is supporting data-driven women’s health platforms. (Link)
Spenser Lin No Comments

Q3 2026 Health IT, Digital Health, and RCM Quarterly Newsletter

Recently released 𝗤𝟯 𝟮𝟬𝟮𝟲 𝗛𝗲𝗮𝗹𝘁𝗵 𝗜𝗧, 𝗗𝗶𝗴𝗶𝘁𝗮𝗹 𝗛𝗲𝗮𝗹𝘁𝗵 𝗮𝗻𝗱 𝗥𝗖𝗠 𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝗠&𝗔 𝗮𝗻𝗱 𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗨𝗽𝗱𝗮𝘁𝗲:

Q3 2026 brought the first real signs of recovery from the “SaaSpocalypse” that hit software and tech-enabled services valuations over the past year. 

LECO Index rose +2.5% in Q3 (still –19.7% TTM), trading at 12.5x EV/EBITDA (around 24% below its 5-year average) and 2.9x EV/Revenue.

Veeva Systems (NYSE: VEEV) gained 60.8% in the quarter, Waystar (NASD: WAY) climbed 23.4%, and other scaled names showed renewed investor willingness to pay for durable growth and proven AI monetization, while sub-scale and loss-making companies continued to be marked down.

Scaled, recurring-revenue platforms, especially Life Science focused, led the rebound. 

• Oura postponed its Nasdaq IPO one day before its planned listing, citing uncertainty in the IPO market despite management stating the company was profitable and demand was strong.

• Several larger PE-backed sale processes were pulled during the quarter as initial price indications came in below expectations; in other cases, owners chose to pause and deepen platform integration and AI implementation before returning to market with a stronger margin and technology story rather than accept a discounted multiple today.

HCIT activity accelerated through the quarter (34 deals in July, 41 in August, 43 in September) with ~$9.0B in disclosed value across 43 priced deals.

In RCM: 26 transactions totaling ~$1.16B, with 48% of disclosed value coming from a single deal (IKS Health ~$557M acquisition of TruBridge).

𝗡𝗼𝘁𝗮𝗯𝗹𝗲 𝘁𝗿𝗮𝗻𝘀𝗮𝗰𝘁𝗶𝗼𝗻𝘀 𝗮𝗻𝗱 𝗳𝗶𝗻𝗮𝗻𝗰𝗶𝗻𝗴𝘀:

•Datavant secured a $2.7B development-capital raise from KKR, New Mountain Capital, and Neuberger.

•Dassault Systèmes agreed to acquire ArisGlobal for ~$2.0B plus a $200M earn-out.

•UHS acquired Talkspace for $835M.

•Francisco Partners agreed to take Weave private ($650M).

•GI Partners and Ardan Equity acquired Clinical ink ($500M).

•Frazier Healthcare Partners acquired MatrixCare from Resmed ($490M).

•Candid Health raised $120M Series D for autonomous revenue cycle management.

===

Full index available with public company comps, valuation multiples, and sector performance data.

#HealthIT #DigitalHealth #HCIT #RCM #RevenueCycleManagement #HealthcareMergers #HealthcareAcquisitions #HealthTech #InvestmentBanking #PrivateEquity #MedTech #HealthcareServices #QuarterlyUpdate #LECO

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update October 12th, 2026

Healthcare Weekly News and Deals – Oct 12th, 2026

  1. Clayton, Dubilier & Rice and McKesson (NYSE: MCK) have agreed to take infusion provider Option Care Health (NASD: OPCH) private in a $5.8 billion deal at $32.05 per share, with CD&R holding 51% and McKesson about 49%. Clayton, Dubilier & Rice and McKesson (MCK) will acquire Option Care Health (OPCH), the largest independent U.S. provider of home and alternate-site infusion services, for $32.05 per share, a 37% premium to its prior close, valuing the deal at $5.8 billion. McKesson plans to invest about $1.4 billion for its roughly 49% interest, and the agreement sets out a framework for McKesson to later buy CD&R’s stake. Option Care treats more than 308,000 patients a year across all 50 states and generated over $5.6 billion of 2025 net revenue. McKesson framed the investment around its specialty and complex-therapy strategy. Closing is expected in the first half of 2027. (Link)
  2. STERIS (NYSE: STE) has agreed to acquire Xodus Medical for $2.1 billion at closing, or about $1.8 billion net of expected tax benefits, plus an earnout of up to $150 million. Xodus was founded in the early 1990s and is based in New Kensington, Pennsylvania, outside Pittsburgh. It builds devices meant to keep patients and operating-room staff safer during surgery. The core product is the Pink Pad, a positioning system used to hold patients in place and reduce pressure injury. A later version combines that pad with underbody warming to address perioperative hypothermia. Hospitals buy the line as a consumable rather than as capital equipment. STERIS already sells infection-prevention products and surgical supplies, so the tuck-in adds a branded safety line. Xodus is expected to do about $245 million of revenue in 2026, with adjusted EBIT of about $135 million. STERIS plans to fund the purchase mainly with debt. Completion is aimed at December 31, 2026 and still needs regulatory sign-off. (Link)
  3. Viatris (NASDAQ: VTRS) has agreed to acquire Pacira BioSciences (NASDAQ: PCRX) for $36.50 a share in cash, or $1.65 billion. Pacira’s commercial book is built on two non-opioid pain drugs. EXPAREL is a liposomal bupivacaine injection used for local pain control after surgery. ZILRETTA is an extended-release steroid injected into the knee for osteoarthritis. The two products booked about $692 million in 2025, and Pacira reported full-year revenue of about $726 million. Both are already on the market, so this is a product acquisition rather than a pipeline bet. The cash price is a 45 percent premium to the prior close. Viatris, based in Pittsburgh, has been shifting from generics and established brands toward a smaller innovative-medicines franchise, and has an oral meloxicam under FDA review with a December 27 decision date. Generic erosion of EXPAREL is expected to begin in early 2030 under earlier patent settlements. Close is expected by the end of 2026. (Link)
  4. BDT & MSD Partners has agreed to acquire a majority stake in Sunrise Senior Living from the Public Sector Pension Investment Board (PSP Investments) in a deal reportedly valuing the operator above $1 billion, with Sunrise management owning the balance. Funds affiliated with BDT & MSD Partners signed a definitive agreement to buy Sunrise Senior Living from Canada’s PSP Investments, which first invested in 2014 and became sole owner in 2023. CEO Jack Callison Jr. and senior executives will invest significant personal capital alongside BDT & MSD’s majority position. Press reports cite a valuation above $1 billion. Sunrise operates more than 230 communities in North America, serving over 22,000 residents and has a pipeline of 50-plus communities with expected development costs of about $7.5 billion. (Link)
  5. Healthcare Services Group (NASD: HCSG) has acquired Mansfield, Massachusetts-based dining and hospitality manager NEXDINE Hospitality for $93.5 million upfront plus a performance-based earnout. Healthcare Services Group (HCSG), the Bensalem, Pennsylvania-based provider of housekeeping, laundry and dining services to healthcare facilities, acquired privately held NEXDINE Hospitality, announced on October 7, 2026, paying $93.5 million upfront in cash on hand, with additional consideration if NEXDINE meets certain performance targets. NEXDINE, a dining and hospitality service management company with a strong senior living presence, is expected to contribute more than $150 million of annual revenue, implying an upfront price of about 0.6x sales. It will operate as a wholly owned subsidiary under its own brand, led by founder and CEO David Lanci. HCSG framed the deal as an expansion into senior living and hospitality-driven care markets. (Link)
  6. Tiffin, Ohio-based Surgence Innovations has secured a $15 million investment from private funds advised by Ohio investor The O.H.I.O. Fund, spinning out as an independent company from Ohio distributor Concordance Healthcare Solutions. Surgence, a healthcare supply chain platform built on the Palantir (NASD: PLTR) Foundry operating system, announced the $15 million on October 6, 2026, with the capital establishing it as an independent corporation. It was incubated under Tiffin, Ohio-based Concordance Healthcare Solutions, an independent distributor with 15 distribution centers licensed in 48 states, which keeps a significant ownership stake and remains a strategic and commercial partner. The O.H.I.O. Fund invests exclusively alongside businesses that call Ohio home; partner Mike Venerable framed the deal as long-term capital supporting Ohio’s healthcare leadership. Proceeds will fund product development, customer growth, hiring and innovation across the healthcare supply chain. (Link)
  7. Standard BioTools (NASDAQ: LAB) has agreed to sell its Microfluidics business to ARCHIMED. The unit being carved out makes integrated fluidic circuits, small chips that run hundreds to thousands of reactions from a single sample. Research labs use them for genotyping, gene-expression work and library preparation ahead of next-generation sequencing. The technology came in through Fluidigm, the predecessor company, and has been cited in thousands of genomics papers. The buyer is a healthcare-only private equity firm founded in 2014 and based in Lyon, France. It invests in life-science tools, diagnostics and medtech on both sides of the Atlantic, and is taking the unit as a standalone business rather than folding it into an operating company. The Boston seller has been pruning a portfolio assembled through earlier combinations. Closing is expected in about 30 days. No price was given. (Link)
  8. Spectrum Equity has made a strategic growth investment in healthcare supply chain data provider Symmetric Health Solutions, the company’s first institutional capital. Spectrum Equity, a growth equity firm founded in 1994 that focuses on AI, software and data businesses, backed Symmetric in a deal announced on October 6, 2026; the size was not disclosed. Founded in 2018 by former Accenture supply chain consultants and Carnegie Mellon alumni, Symmetric reached profitability without outside capital and maintains a database of nearly 20 million healthcare items, each with up to 1,800 metadata attributes, used by more than 850 hospitals. Managing Director Michael Radonich said the company has become the system of record for supply data at several of the largest U.S. health systems. Proceeds fund go-to-market, customer success and new products, including a supply chain control tower. (Link)
  9. FFL Partners has made a growth investment in Nashville-based Ally Technical, the healthcare technology management company formerly known as Althea US. FFL Partners backed Ally Technical alongside the company’s rebrand, in a deal announced on October 6, 2026 with undisclosed terms. Ally Technical provides service, parts, board-level and depot repair, technical support and training for medical equipment from major manufacturers, built on deep expertise in contrast injectors, and supports a large installed base of aging devices across the U.S. FFL partner Karen Winterhof said providers are increasingly turning to independent service organizations for cost-efficient maintenance and parts. The investment came out of FFL’s SEED sector-exploration strategy, and the partners plan organic growth plus M&A, including expansion into new device modalities and under-penetrated markets. CEO Dan Siler continues to lead. (Link)
  10. Harbor Health has agreed to acquire 27 Village Medical clinics in the Houston area. The sites are primary-care offices spread across Harris, Montgomery, Fort Bend and Brazoria counties. They had been run as part of a larger clinic network. The buyer is a Texas primary-care and insurance company that already pairs offices with its own plans in Austin, Dallas, San Antonio and El Paso. This is the fifth market on that model. It bought 32 clinics from the same seller in those other cities in 2025. Plans carry no deductible, and referred specialty care is covered at no cost when one of its clinicians makes the referral. Individual and family enrollment for the new market opens November 1, with coverage effective January 1. No price was disclosed, and the release does not break out patient volume or revenue for the sites. (Link)
  11. Bambu Capital-owned Lemonaid Health has acquired the fitness and longevity business of Dr. B, the telehealth company founded by Zocdoc founder Cyrus Massoumi. Lemonaid Health, the digital pharmacy and telehealth platform owned by Bambu Capital, bought Dr. B’s fitness and longevity business on October 5, 2026, including its national fitness-brand partnerships and longevity membership base; terms were not disclosed. Dr. B built an early scaled gym-as-clinic model in which members can use pre-tax HSA/FSA dollars for gym memberships through letters of medical necessity. The deal gives Lemonaid a gym partner network reaching more than 5 million members and a metabolic-health patient base. Bambu Managing Partner Dylan Runne said it fits the thesis behind Bambu’s Lemonaid purchase: pairing a licensed clinical and pharmacy engine with partners that own the customer relationship. (Link)
  12. Varsity Healthcare Partners-backed United Aesthetics Alliance has acquired St. Louis-based Parkcrest Plastic Surgery and the Aesthetics Center. United Aesthetics Alliance, a physician practice management holding company sponsored by lower middle-market healthcare private equity firm Varsity Healthcare Partners since 2023, completed the acquisition, reported on October 7, 2026; terms were not disclosed. Founded in 2001, Parkcrest provides plastic surgery and medical spa services and is led by co-founding board-certified plastic surgeons Dr. David Caplin and Dr. Patricia McGuire. The deal is the platform’s first acquisition of 2026 and establishes its footprint in Missouri, in line with its strategy of consolidating market-leading plastic surgery practices and affiliated medical aesthetic providers. Parkcrest will keep operating from its current St. Louis location under its existing brand. (Link)
  13. GreyLion Capital-backed Trifecta Collective has acquired the Medical Spa Show from the American Med Spa Association (AmSpa) and entered a long-term partnership with the association. Trifecta Collective, a multi-sector trade show organizer founded in 2021 by industry veteran Rick McConnell and supported by financial partner GreyLion Capital, announced the acquisition on October 6, 2026; terms were not disclosed. Launched by AmSpa in 2018, the Medical Spa Show has drawn nearly 10,000 attendees from more than 5,200 practices and hosted over 750 exhibiting brands; its 10th edition at Wynn Las Vegas in April 2027 is expected to attract more than 3,500 medical aesthetics professionals. McConnell called medical aesthetics one of the fastest-growing segments in healthcare and wellness. AmSpa stays involved under the partnership, and the current show team remains. (Link)
  14. 1 Natural Way, based in Maumee, Ohio, has acquired New England Surgical. The buyer was started in 2014 by Ryan Wright to ship insurance-covered breast pumps and related maternal products. It now works with major carriers in all 50 states, carries pumps from more than a dozen manufacturers, and runs an in-house program with certified lactation consultants. The target, in Fall River, Massachusetts, has sold medical supplies and home equipment across Massachusetts and Rhode Island for more than four decades. What is being bought is the regional payor contracts, not a new product line. Those contracts cover insured patients the Ohio company could not previously bill. The buyer said the add-on widens the set of mothers it can serve at little or no out-of-pocket cost. No price was disclosed. (Link)
  15. RiverGlade Capital has formed Sentinel Care Group, a healthcare franchise platform led by former Right at Home CEO Brian Petranick. Chicago-based RiverGlade Capital, a private equity firm founded in 2017 that makes control and select minority investments in lower middle-market healthcare companies, launched Sentinel Care Group on October 8, 2026. According to PE Hub, the platform will acquire and partner with existing businesses and emerging franchisors, and develop new franchise concepts from scratch. Petranick spent more than two decades at Right at Home, helping grow it from a single Omaha location into an international in-home care franchise with more than 650 territories, and served as president and CEO until 2022. RiverGlade’s franchise experience includes home care franchisor Home Helpers Home Care, acquired in 2021. Capital commitments were not disclosed. (Link)
  16. Emergence, the permanent-capital enterprise backed by The Pritzker Organization, has acquired Charlotte, North Carolina-based patient-reported outcomes software company Clinect Healthcare. Emergence, which provides long-term capital and operating support to software and technology-enabled businesses rather than following a hold-and-exit model, announced the acquisition of Clinect Healthcare on October 8, 2026; terms were not disclosed. Founded in 2012 by CEO Brian Schmitz, Clinect runs an Outcomes Intelligence Platform combining digital intake, patient-reported outcomes, patient experience and reputation management tools, with more than 600 validated outcome measures integrated into practice management and EHR systems. Emergence Operating Partner David Henriksen cited the opportunity as payers demand proof of care results. The deal adds to Emergence’s healthcare software roster after its November 2025 purchase of MedEvolve, and funds data science, AI and interoperability investment. (Link)
  17. Sienna Senior Living (TSX: SIA) has agreed to acquire Brighton Retirement & Active Living, a 165-suite seniors’ residence in Brighton, Ontario, for approximately C$73.8 million. Sienna Senior Living (SIA), the Markham, Ontario-based seniors’ housing owner and operator, signed an agreement on October 8, 2026 to buy Brighton Retirement & Active Living, about 150 km east of Toronto, for a gross price of roughly C$73.8 million, or C$447,000 per suite. Terms add C$1.5 million of income support for the lease-up of the seniors’ apartments and commercial units, plus a C$5.0 million earnout tied to financial targets. The property has 124 retirement suites opened in 2024 and about 95% occupied, 41 seniors’ apartments opened in 2025 and five commercial units. Sienna is funding the deal from cash and credit facilities, with closing expected in Q4 2026. (Link)
  18. Grovecourt Capital-backed Guide Architecture has acquired medical equipment planning firm MAIA as an add-on to its Dallas-based healthcare design platform. West Palm Beach, Florida-based Grovecourt Capital, a lower middle-market investor in founder-led business services and healthcare services companies, added MAIA to portfolio company Guide Architecture in a deal reported on October 8, 2026; terms were not disclosed. MAIA is a 25-person healthcare consulting firm providing medical equipment planning, procurement support, BIM and Revit services, inventory assessment and implementation support. Guide, founded in Dallas in 2014, plans and designs hospitals, outpatient centers, behavioral health facilities and medical office buildings for health systems nationwide. Grovecourt invested in Guide in April 2026, with existing leadership remaining significant owners, and set out a strategy of acquisitions that deepen healthcare expertise and client relationships. (Link)
  19. Oak Hill Capital-backed Petauri has acquired health economics and market access consultancy Franklin Pharmaceutical Consulting. Nashville-based Petauri, the life sciences commercialization platform Oak Hill Capital founded with CEO Dan Renick, announced the acquisition of Franklin Pharmaceutical Consulting (FPC) on October 8, 2026; terms were not disclosed. Oak Hill is committing more than $250 million of equity to Petauri from its latest fund, OHCP VI, and the platform has previously bought The Kinetix Group, the FORCE Communications agencies, Mtech Access, Delta Hat, the Brightly Network agencies, Formulary Insights and Artia Solutions. FPC provides health economics and outcomes research, real-world evidence strategy, payer value communications and dossiers. It folds into Petauri Evidence, with founder Meg Franklin becoming President of Petauri Evidence US. (Link)
  20. Lee Equity Partners-backed Marwood Group has acquired Ronan Healthcare Compliance, expanding its compliance advisory capabilities. New York-based Marwood Group, a healthcare advisory and consulting firm that recently took a strategic investment from Lee Equity Partners, acquired Ronan Healthcare Compliance in a deal announced October 12, 2026. Ronan, founded by Ross and Susan Ronan, provides outsourced compliance officer services, risk assessments, buy-side and sell-side diligence, and program development to more than 60 healthcare organizations across 21 specialties. The full Ronan team joins Marwood, with Ross Ronan becoming Managing Director and Head of Compliance Services. Terms were not disclosed. Bailey & Co advised Ronan. (Link)

Venture Deals and Other

  1. Andreessen Horowitz has led a $120 million Series B in San Francisco-based General Medicine, joined by Matrix, VXI Capital, Eli Lilly (NYSE: LLY), BoxGroup and Ohio-based Mercy Health through Granger Management. a16z General Partner Vineeta Agarwala led the round, announced on October 6, 2026, which lifts General Medicine’s total funding to $152 million. Eli Lilly (LLY) and Cincinnati, Ohio-based Mercy Health, investing through Granger Management, join as strategic backers alongside Matrix, VXI Capital and BoxGroup. Founded in 2023 and launched nationwide in May 2025, General Medicine runs a healthcare store listing more than 2,900 medications, labs, telehealth visits, specialist e-consults and procedures with upfront insurance and cash prices. It has signed up hundreds of thousands of customers with an average NPS of 80. Former Matrix General Partner TJ Parker became full-time CEO in October. Proceeds expand the store into new care categories. (Link)
  2. Dr. Patrick Soon-Shiong’s NantWorks has led a $75 million Series B in San Francisco-based Multiply Labs, joined by AstraZeneca (NASD: AZN), Lingotto, Teradyne (NASD: TER), Strange Ventures, Casdin Capital, Lux Capital, Fifty Years, Ora Global and Founders Fund. NantWorks led the round, announced on October 6, 2026, which takes Multiply Labs’ total funding above $100 million since its 2016 founding; valuation was not disclosed. New investors AstraZeneca (AZN), Lingotto, Teradyne (TER) and Strange Ventures joined returning backers Casdin Capital, Lux Capital, Fifty Years, Ora Global and Founders Fund. AstraZeneca is also a customer, underscoring the strategic weight of the cap table. Multiply Labs builds robotic clusters that automate manual steps in biologics manufacturing, initially for cell and gene therapies and now antibodies, viral vectors and mRNA, with systems owned and run in-house by drugmakers. Proceeds fund manufacturing capacity, product development and engineering, regulatory and commercial hiring. (Link)
  3. Sequoia Capital, First Round Capital and Hummingbird Ventures have backed clinical AI company Healthleap in $38 million of combined seed and Series A funding. Healthleap disclosed the $38 million on October 8, 2026, with Sequoia partner Alfred Lin and First Round co-founder Josh Kopelman both endorsing the investment. Founded in 2022 by siblings Josiah and Jemima Meyer, the company continuously analyzes patient records, including notes, labs, vitals and orders, to flag undiagnosed conditions and push risk scores into EHR workflows. It started with disease-related malnutrition, which costs the U.S. system up to $58 billion annually; one Penn Medicine hospital attributed $23.8 million a year in reimbursement and length-of-stay benefits to the platform. Proceeds fund expansion to more than 40 conditions and hiring to reach hundreds of hospitals. (Link)
  4. The Florida Opportunity Fund and Tampa General Hospital’s TGH Ventures have co-led a $35 million growth equity investment in Spark Pediatrics, with Town Hall Ventures, UPMC Enterprises and Memorial Hermann participating. Spark Pediatrics, which operates Prescribed Pediatric Extended Care centers for children with medical complexities, including a Clearwater, Florida location, announced the $35 million equity investment on October 9, 2026. The Florida Opportunity Fund and TGH Ventures led, with continued participation from existing investor Town Hall Ventures and all of Spark’s existing strategic partners, including UPMC Enterprises and Memorial Hermann. The health system backers give Spark strategic relationships across Florida, Pennsylvania and Texas. Proceeds will support Spark’s leading presence in Florida, growth in Texas and expansion into Pennsylvania, Louisiana and other new states. Valuation and round designation were not disclosed. (Link)
  5. Oak HC/FT has led a $31 million Series A in San Francisco-based Vitalize, joined by Norwest, .406 Ventures, Constellation Ventures, Y Combinator, Rock Health Capital and MemorialCare Innovation Fund. Oak HC/FT partner Vig Chandramouli led the round, announced on October 6, 2026, with health system venture arm MemorialCare Innovation Fund participating as a strategic investor. Vitalize sells an AI-native platform that automates scheduling and forecasts demand to coordinate staffing and bed capacity across health systems, integrating with EMR and time-and-payroll systems. It manages millions of shifts a week across dozens of enterprise health systems; St. Luke’s Health reported a 54% cut in premium labor spend within 12 weeks. Oak HC/FT, with more than $7 billion under management, views hospital labor, a nearly $1 trillion cost line, as an underpenetrated software market. Proceeds fund growth, deployment and throughput AI. (Link)
  6. Maveron has led a $25 million Series A in New York-based oral care membership company Wally, joined by Bling Capital and angel investors including Hims & Hers Health (NYSE: HIMS) co-founder Jack Abraham. Maveron partner Jason Stoffer backed Wally’s model of replacing insurance-driven dentistry with a $249 annual membership covering unlimited cleanings, AI-supported diagnostics, exams and whitening; the round was announced on October 7, 2026. Bling Capital and angels including Jack Abraham participated. Wally has passed 50,000 members who visit three times a year, reports a 97% hygienist retention rate and operates 15 locations in co-working spaces across New York City, Philadelphia, Jersey City and Chicago. It also announced a strategic partnership with EMS Dental. Proceeds fund expansion from 15 to 100 locations by end-2027, including Washington DC, Atlanta, Austin and Miami. (Link)
  7. F-Prime has led a $20 million Series A in Allentown, Pennsylvania-based AblePay Health, with participation from A1 Health Ventures and .406 Ventures. F-Prime principal Nikhil Marathe led the round, announced on October 7, 2026, as AblePay enters its second decade. Chicago-based A1 Health Ventures, whose limited partners are health systems operating more than 110 hospitals, and Boston’s .406 Ventures, with over $1.3 billion under management, joined. Founded in 2016, AblePay integrates with providers to guarantee non-recourse payment on an accelerated timeline while offering enrolled patients flexible payment options, savings on out-of-pocket costs and free billing advocacy. The company cites $591 billion of U.S. out-of-pocket healthcare spending in 2025, up 6%. Proceeds will expand its reach to more health systems and deepen its technology platform. (Link)
  8. Norrsken VC has led a $20 million Series A in Paris- and New York-based AI medical receptionist company Vocca, joined by Heal Capital, Speedinvest and firstminute capital. The round, announced on October 6, 2026, lifts Vocca’s total funding to $25 million about a year after its previous raise; valuation was not disclosed. Founded in July 2024 by Eliott Hoffenberg and Hugo Danet, Vocca builds specialty-specific AI agents that answer patient calls, book and reschedule appointments and handle routine requests for medical practices. It has grown from 2,000 to 15,000 practitioners in a year across the U.S. and Europe and now handles more than one million patient conversations a month. Proceeds will deepen its U.S. presence through its New York office, add specialties and channels beyond voice, and fund about 40 hires. (Link)
  9. NFX has led a $7 million seed round in Altro Health, with Founder Collective and Primetime Partners’ Abby Miller Levy participating. NFX general partner James Currier said the firm backed Altro, formerly Lyv Health, for its position in a large new consumer category with no clear leader; the round was announced on October 6, 2026. Altro operates a Shopify-style platform that lets personal trainers, gyms and medspas offer clinician-prescribed peptides, GLP-1s, hormone therapy and lab testing under their own brands, with a board-certified clinical team supervising each service and products sourced from licensed 503A and 503B pharmacies. More than 500 businesses already use the platform, with plans starting at $319 a month. Proceeds fund product development, hiring, and sales and marketing. (Link)
  10. Listen Ventures, Cake Ventures, LAUNCH, Actions Capital, Hannah Grey VC, SemperVirens, Brock Recovery Group and Pave Health Ventures have backed New York-based deprescribing platform Outro in $7 million of pre-seed and seed funding. Outro disclosed the $7 million across pre-seed and seed rounds on October 8, 2026, with participation from Listen Ventures, Cake Ventures, Jason Calacanis’ LAUNCH, Actions Capital, Hannah Grey VC, SemperVirens, Brock Recovery Group and Pave Health Ventures, among others. Co-founded by CEO Brandon Goode and psychiatric deprescribing researcher Dr. Mark Horowitz, Outro runs a virtual clinic that helps patients taper off antidepressants through personalized plans, monitoring and clinician support, and is available in 14 states. It cites roughly 50 million Americans taking antidepressants. Proceeds expand the clinician network, apply AI to tapering workflows and extend the model into other medication classes. (Link)

Market Rumors / IPO

  1. Solventum (NYSE: SOLV) is seeking bids for its Health Information Systems unit, pitched at a $5.5 billion to $7 billion valuation. Solventum, the medical products and technology company spun out of 3M, is collecting initial bids for its Health Information Systems division, according to reports on October 12, 2026. The unit provides hospitals and health systems with medical coding, billing, documentation and revenue cycle management software and generated about $1.4 billion of sales last year. Solventum announced plans to separate the business in August 2026 as it focuses on medsurg and dental. Shares slipped after the report. No buyer has been named, and a sale or spin remains possible. (Link)
  2. Bambusa Therapeutics has filed a Form S-1 for a proposed Nasdaq IPO under the symbol B BTX.Bambusa was incorporated in Boston in March 2024. It is a clinical-stage company working on long-acting bispecific antibodies for immunology and inflammation. BBT001 targets IL-4Rα and IL-31 for atopic dermatitis and chronic spontaneous urticaria. BBT002 targets IL-4Rα and IL-5 for COPD, nasal polyps and asthma. Two earlier programs are still preclinical. Private investors including RA Capital, BVF Partners, ATHOS and Dawn Biopharma have put in about $136 million. Cash was $71.5 million at June 30. The filing does not set a share count or a price. Named underwriters include BofA Securities, Evercore, UBS and Cantor. (Link)

CLICK HERE to sign up
for all news and updates